Download VIENNA, AUSTRIA

EADO
FINAL PROGRAM
16th World Congress on Cancers of the Skin®
12th Congress of the European
Association of Dermato-Oncology
Or
ga
ed
niz
by
H
rt
ube
m
Pe h a
b e rg e
r a n d Ch ris t o p h H o e l l e
r
AUGUST 31– SEPTEMBER 3, 2016
VI EN N A , AUST RI A
.wc c
www
6.c
1
0
s2
om
Visit BMS at booth No22 to learn more
The first and only approved I-O combination
offering superior efficacy versus YERVOY1,2
OPDIVO as monotherapy or in combination with ipilimumab is indicated for
the treatment of advanced (unresectable or metastatic) melanoma in adults2
Relative to nivolumab monotherapy, an increase in progression-free survival (PFS)
for the combination of nivolumab with ipilimumab is established only in patients
with low tumour PD-L1 expression2
I-O – Immuno-oncology
References: 1. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined Nivolumab and lpilimumab or Monotherapy in Untreated
Melanoma. N Engl J Med 2015;373:23-34. 2. OPDIVO® Summary of Product Characteristics. Available at the booth.
ABBREVIATED SMPC:
▼This medicinal product is subject to additional monitoring. This will allow quick
identification of new safety information. Healthcare professionals are asked to report any
suspected adverse reactions. See section 4.8 in the SmPC for how to report adverse
reactions.
NAME OF THE MEDICINAL PRODUCT: OPDIVO 10 mg/mL concentrate for solution for
infusion. Pharmacotherapeutic Group: Antineoplastic agents, monoclonal antibodies.
ATC code: L01XC17 QUALITATIVE AND QUANTITATIVE COMPOSITION: Each mL of
concentrate contains 10 mg of nivolumab. One vial of 4 mL contains 40 mg of nivolumab.
One vial of 10 mL contains 100 mg of nivolumab. Nivolumab is produced in Chinese
hamster ovary cells by recombinant DNA technology. List of excipients: Sodium citrate
dihydrate, Sodium chloride, Mannitol (E421), Pentetic acid (diethylenetriaminepentaacetic
acid), Polysorbate 80, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH
adjustment) Water for injections. THERAPEUTIC INDICATIONS: Melanoma: OPDIVO as
monotherapy or in combination with ipilimumab is indicated for the treatment of advanced
(unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy,
1506AT16PR06864-01 06/16
an increase in progression-free survival (PFS) for the combination of nivolumab with
ipilimumab is established only in patients with low tumour PD-L1 expression (see
sections 4.4 and 5.1 in the SmPC). Non-Small Cell Lung Cancer (NSCLC): OPDIVO is
indicated for the treatment of locally advanced or metastatic non-small cell lung cancer
(NSCLC) after prior chemotherapy in adults. OPDIVO as monotherapy is indicated
for the treatment of advanced renal cell carcinoma after prior therapy in adults.
CONTRAINDICATIONS: Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1 in the SmPC. MARKETING AUTHORISATION HOLDER: Bristol-Myers
Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH,
United Kingdom. CONTACT IN AUSTRIA: Bristol-Myers Squibb GesmbH, Vienna, Tel. +43
1 60143 -0 NR, prescription only. DATE OF LAST REVISION: May 2016
Further information, especially in regards to special warnings and precautions for use,
Interactions with other medicinal products or other forms of interaction, pregnancy and
lactation as well as undesirable effects are to be extracted from the published Summary
of Product Characteristics (SmPC).
© 2016 Bristol-Myers Squibb Company
EADO
Table of Contents
Congress Information
Societies and Contacts 2
Welcome Message 5
Acknowledgements 6
Information from A to Z 7
Public Transport Vienna 11
Hofburg Overview 12
Scientific Program
Wednesday, August 31, 2016 14
Thursday, September 1, 2016 19
Friday, September 2, 2016 33
Saturday, September 3, 2016 49
List of Chairs and Invited Speakers 54
Poster Exhibition 56
Industrial Exhibition
List of Exhibitors 85
Exhibition Floor Plan 84
FSA Disclosure Requirement 87
Session Types
SY
PL
Symposium
Plenary Lecture
FC
SAT
Free Communication
Industry Symposium
OT
Others
Congress Information
Societies and Contacts
Societies
CONGRESS INFORMATION
EADO
Euro p ean A s s o ciation of
D er mato O nc olo g y
European Association of Dermato Oncology (EADO)*
President
Garbe, Claus
Vice-President
Stratigos, Alexander
Treasurer
Hauschild, Axel
General Secretary
Peris, Ketty
Secretary for Members
Malvehy, Josep
Secretary for European
Integration
Forsea, Anna-Maria
Past President
Grob, Jean-Jacques
Past President
Pehamberger, Hubert
*According to the respective website
2
Board Members
Alper, Sibel
Arenberger, Peter
Bataille, Véronique
Bylaitė-Bučinskienė,
Matilda
Del Marmol, Véronique
Dreno, Brigitte
Dummer, Reinhard
Forsea, Ana-Maria
Garbe, Claus
Grob, Jean-Jacques
Harwood, Catherine
Hauschild, Axel
Hoeller, Christoph
Kandolf-Sekulovic, Lidija
Kaufmann, Roland
Lebbé, Céleste
Malvehy, Josep
Moreno-Ramírez, David
Olah, Judit
Pehamberger, Hubert
Pellacani, Giovanni
Peris, Ketty
Robert, Caroline
Stockfleth, Eggert
Stratigos, Alexander
Vieira, Ricardo
Weinlich, Georg
Zalaudek, Iris
Skin Cancer Foundation*
President
Robins, Perry
Senior Vice Presidents
Amonette, Rex A.
Hale, Elizabeth K.
Hanke, C. William
Moy, Ronald L.
Perez, Maritza I.
Sarnoff, Deborah S.
Vice Presidents
Goldberg, Leonard H.
Halpern, Allan C.
Quintana, Adelle T.
Weinkle, Susan H.
General Counsel
Weiner, Bennett Esq.
Secretary
Robins, Elizabeth Esq.
Executive Director
Latore, Dan
Congress Information
Societies and Contacts
Christoph Hoeller, MD
Professor of Dermatology
Medical University Vienna
Department of Dermatology
Währinger Gürtel 18–20
Vienna, Austria
E: [email protected]
Legal Organizer (PCO)
MCI Deutschland GmbH
MCI | Berlin Office
Markgrafenstrasse 56
10117 Berlin, Germany
P: +49 (0)30 204590
F: +49 (0)30 2045950
E: [email protected]
Registration and Accommodation
E: [email protected]
Exhibition and Sponsoring
E: [email protected]
© WienTourismus / Christian Stemper
Congress Presidents
Hubert Pehamberger, MD
Professor of Dermatology
Medical Director Rudolfinerhaus
Medical University Vienna
E: [email protected]
CONGRESS INFORMATION
Contacts
3
MORE THAN MEETS THE EYE –
TREATING ACTINIC KERATOSIS AND BEYOND
Satellite symposium
Thursday, 1st September, 09:00–10:00
Geheime Ratstube
Hofburg Vienna, Austria
Chair:
Professor Claus Garbe | Germany
Please join us as we explore the concept of field
cancerisation and personalised field therapy for
the treatment of actinic keratosis (AK), with our
renowned expert faculty who will discuss the current
unmet needs in AK and the risk factors that may
be linked to the recurrence of this condition and
its progression to squamous cell carcinoma
AGENDA
Time
Session
Speaker
09:00
Welcome and introduction
Professor Claus Garbe (Chair)
Germany
09:15
What lies beneath? Optimising
diagnosis of field cancerisation
AK and beyond: Tailored therapy
Dr Iris Zalaudek
Austria
to optimise patient outcomes
Professor Jean-Jacques Grob
France
09:45
Panel discussion
All
09:55
Closing remarks
Professor Claus Garbe (Chair)
Germany
09:30
Release date: August 2016
Congress Information
Dear Colleagues,
The “World Congress on Cancers of the
Skin” and the “Congress of the European
Association of Dermato-Oncology” (EADO)
have become major interdisciplinary
meetings for clinicians and basic scientists
working in the challenging fields of
Melanoma and Non-Melanoma Skin
Cancer. Both meetings will be held together
as a Joint Meeting covering the entire
spectrum of cutaneous malignancies.
It is our pleasure to host this unique Joint
Meeting of the 16th World Congress on
Cancers of the Skin and the 12th EADO
conference in the historic Hofburg
Conference Center in the heart of Vienna.
We feel privileged and honored that many
of the world’s leading investigators in the
field will actively participate in this meeting.
Clinicians and researchers will focus on the
state of the art in prevention, recognition,
and treatment of cutaneous neoplasms
covering Melanoma and Non Melanoma
Skin Cancer as well as Lymphomas and Rare
Skin Tumors.
As the organizers of this meeting we
cordially invite you to share with us days of
scientific communication in the beautiful
city of Vienna.
Hubert Pehamberger
Christoph Hoeller
5
CONGRESS INFORMATION
© WienTourismus/Christian Stemper
Welcome Message
Congress Information
We are delighted to give special thanks to our main sponsors:
CONGRESS INFORMATION
Platinum Sponsors
Gold Sponsors
Silver Sponsor
Bronze Sponsors
BIOPHARMACEUTICALS, INC.
Advancing a New Front
in the
War Against Cancer
6
Acknowledgements
Abstracts
Approved abstracts have been published
online as a supplement to the August issue
of “Melanoma Research”. You may access
these abstracts free of charge until August
2017 by visiting:: journals.lww.com/
melanomaresearch/pages/default.aspx
Act of God
It is mutually agreed that in the event
of total or partial cancellation of the
congress due to fire, strike, natural
disaster (either threatened or actual),
government regulations or incidents
not caused by the organizer, which
would prevent its scheduled opening
or continuance, the congress may be
partially postponed or terminated as
a whole. In this case, participants are
not entitled to reclaim refunds on no
account. Participants are obliged to have
civil liability insurance.
Certificate of Attendance
All registered participants will receive a
certificate of attendance. You are able to
print your certificate at the self-printing
stations in the Hall on the ground floor.
Opening Hours
FRI, September 2
SAT, September 3
12:00 PM–06:30 PM
07:00 AM–01:00 PM
Climate
Vienna belongs to the humid continental
climate. In August the weather is warm.
Average temperatures are 20°C during
the day. At night the temperatures can
decrease to 11°C.
Information from A to Z
Congress Documents
Registration fee for participants covers:
admission to scientific sessions and
satellite symposia, congress bag with
congress documents, admission to the
exhibition.
CONGRESS INFORMATION
Congress Information
Congress Language
The official language of the congress will
be English. Simultaneous translation will
not be provided.
Congress Venue
Hofburg Vienna
Heldenplatz
1010 Vienna, Austria
P: +43 1 5873666
F: +43 1 5356426
Currency
The official currency in Austria is Euro (EUR).
Electricity
In Austria electricity is supplied at 220V,
50Hz. For some devices from abroad
converters will be needed.
Insurance
The congress organizers do not accept
any liability for damages and/or losses of
any kind which may be incurred by the
congress participants or by any persons
accompanying them. Delegates participate
in all events at their risk. Participants
are advised to take out insurances
against loss, accidents or damage that
could occur during the Congress. Verbal
agreements will not be binding unless
7
CONGRESS INFORMATION
Congress Information
Information from A to Z
they are confirmed in writing. Sole place
of jurisdiction is Vienna. Austrian law is
applicable.
as a result of the congress or during all
events. Registration of a participant entails
acceptance of these conditions.
Gastronomy
The catering stations for the coffee and
lunch breaks are located in the Hofburg
Lounge, in the Hofburg Galerie and in the
Seitengalerie. Participants will be offered
snacks and beverages. Catering is not
included in the registration fee.
Lost & Found
A Lost & Found box will be placed at the
registration desk.
Helpful Phone Numbers
Taxi Vienna: +43 66 44 60 43 89
Taxi 40100: +43 140 100
Fire Service: 122
Police:133
Internet Access
Free wireless internet access is available in
the venue. Therefore a password is required.
ƒƒ Name: HofburgSecured
ƒƒ Password: wccs2016
Please ensure the wireless connection on
your device is configured and your device
is correctly protected for wireless usage.
No technical support will be provided.
Liability Disclaimer
The organizers cannot be held liable for
any hindrance or disruption of congress
proceedings arising from political,
social or economic events or any other
unforeseen incidents beyond their control.
The organizers will accept no liability
for any personal injuries sustained or for
loss or damage to property belonging to
congress participants, either during or
8
Media Check
The media check is located in the
Orchestergang on the first floor.
Speakers are requested to hand in their
presentations at least 3 hours before
their talk. Speakers having a presentation
during the first time slot in the morning
are asked to hand in their slides the day
before. Please do not bring a laptop or
other media device to the session room.
Opening Hours
WED, August 31
THU, September 1
FRI, September 2
SAT, September 3
12:00 PM–06:00 PM
07:00 AM–06:00 PM
07:00 AM–06:00 PM
07:00 AM–12:00 PM
Name Badges
The name badge will be the official meeting
document and should be worn at all times
in order to gain entry to the meeting rooms
and the exhibition halls. Admission to the
conference will not be allowed without
badge identification. In case of lost or forgotten badges, an administration fee of
€20 will be charged.
Parking Facilities
There are no parking slots available at the
Congress Venue. Please use the parking
garages nearby:
Garage Robert Stolz-Platz (500 m)*
Price: €3.80/1h (day price: €38)
Garage am Museumsquartier
(Museumsplatz, 500m)*
Price: €4/1h (day price: €22)
Parkgarage Rathauspark
(Universitätsring, 500m)*
Price: €4/1h (day price: €40)
* Opening hours: 24h/7 days a week
Photography, Audio, Video
and Mobile Phone Policy
Audio, photo and video recording by any
device (e.g. cameras, laptops, PDAs, mobile
phones, watches) is strictly prohibited during all oral and poster sessions, unless prior
permission is obtained from the congress
organizer. Use of mobile phones is strictly
prohibited during scientific sessions. Mobile
phones must be switched off while attending sessions.
Program Changes
The organizer reserves the right to make
changes if necessary. No full or partial
refunds are made to the attendees in the
event of cancellations or other changes in
the program. Please note that changes will
be posted at the registration desk and at
the entrance of the session halls. Participants will be informed about the changes.
Public Transportation
Vienna offers an efficient and modern
system of public transportation (called
VOR), including underground (U),
Information from A to Z
metropolitan train (S), trams and buses.
There are also special night buses (N)
which may be used with the standard
tickets. You can purchase public
transportation tickets at most tobacconists
(Tabak-Trafik), VOR ticket offices, ticket
distributor machines at underground
stations and in some hotels; on the tram
(machine in the 1st coach) and on the bus
(from the driver). Tickets must be stamped
at the “blue box” located inside the tram
or bus; for underground and metropolitan
train it is located at the barrier before
accessing the platform.
Registration
You can still register online and directly in
Vienna. However, waiting can be eased,
if participants register online in advance.
Pre-registered participants will receive a
barcode which is required on-site in order
to print the badge. Therefore, it is essential
to have the barcode ready. Self-printing
stations are located directly in front of the
registration desk.
Registration Desk
The registration desk is situated in the Hall
on the ground floor.
P: +43 1 536 44 223
Opening Hours
WED, August 31
THU, September 1
FRI, September 2
SAT, September 3
12:00 PM–06:30 PM
07:00 AM–06:30 PM
07:00 AM–06:30 PM
07:00 AM–01:00 PM
9
CONGRESS INFORMATION
Congress Information
Information from A to Z
CONGRESS INFORMATION
© WienTourismus/Christian Stemper
Congress Information
Registration Fees
Late/On-site Fees
Delegates
€665
Residents*
€300
Students*
€190
Accompanying person
€ 85
Day ticket
€250
tavern (Heurigen) will deliver a marvellous
atmosphere for the evening. You will
appreciate the wonderful Viennese wines
as well as various typical dishes.
The bus-transfer to the location will start at
07:30 PM at Hofburg Vienna.
*Proof of current status needs to be provided along with the
registration.
Smoking
Smoking is strictly prohibited in the
congress venue by law.
Social Program
Get Together
The Get Together will take place on
Wednesday, August 31 at 7:00 PM at the
Hofburg Galerie in the Congress location.
Time Zone
Austria belongs to the Central European
Time Zone (GMT+1).
Networking Evening
The Networking Evening will take place
on Friday, September 2 at 08:00 PM. at
Heuriger Werner Welser, Probusgasse 12,
1190 Vienna. The traditional Austrian
Tipping
In many areas such as gastronomy, in taxis,
at hairdressers, at service stations, tipping
is traditionally expected. Usually, the tip
amounts to about 5 to 10%, according to
the degree of your satisfaction with the
service rendered.
10
Public Transport Vienna
CONGRESS INFORMATION
Congress Information
11
Hofburg Overview
CONGRESS INFORMATION
Congress Information
Registration
1 Hofburg Foyer (Halle)
Sessions
2Festsaal
3Zeremoniensaal
4Rittersaal
5 Geheime Ratstube
12
Industrial Exhibition
6 Hofburg Galerie
7Seitengalerie
8 Oberes Platzl
Poster Exhibition
9Marmorsaal
10Antekammer
Media Check
11Orchestergang
EADO
SCI ENTI FI C PRO G R A M
Wednesday, August 31, 2016 14
Thursday, September 1, 2016 19
Friday, September 2, 2016 33
Saturday, September 3, 2016 49
List of Chairs and Speakers 54
Poster Exhibition 56
Scientific Program
04:00 PM
WED
THU
06:00 PM
FRI
07:00 PM
SAT
Rittersaal
SY3
Dermoscopy Part I Basics
01:30 PM–03:30 PM
Geheime Ratstube
03:00 PM
05:00 PM
08:00 PM
09:00 PM
POSTER
INDEX
Zeremoniensaal
SY2
Biology of Skin Cancer
Development
01:30 PM–03:30 PM
14
Coffe Break
03:30 PM–04:30 PM
SAT2
SAT1
Novartis Symposium:
Merck-Pfizer Symposium:
Melanoma Changing
Current and Potential
Landscape: Individualized Future Treatment Options
Decision Making
for Merkel Cell Carcinoma
03:30 PM–04:30 PM
03:30 PM–04:30 PM
PL1
Plenary
04:30 PM–06:00 PM
OT1
Opening Ceremony
06:00 PM–07:00 PM
OT2
Get Together
(Hofburg Galerie)
07:00 PM–09:30 PM
Exhibiton – Hofburg Galerie
SCIENTIFIC PROGRAM
Festsaal
SY1
Epidemiology of Skin
02:00 PM Cancer, Public Education
and Primary Prevention
01:30 PM–03:30 PM
Wednesday, August 31, 2016
Scientific Program
SY1
SYMPOSIUM
Epidemiology of Skin Cancer, Public Education
and Primary Prevention
Festsaal
P. Robins (USA)
V. Del Marmol (Brussels, Belgium)
01:30 PM–01:50 PM
SY1-1
Epidemiology of skin cancer worldwide
A. Halpern (New York, USA)
01:50 PM–02:10 PM
SY1-2
Skin cancer prevention in Australia
M. Janda (Brisbane, Australia)
02:10 PM–02:30 PM
SY1-3
Skin cancer prevention in the US
A. Geller (Boston, USA)
02:30 PM–02:50 PM
SY1-4
Euro-melanoma, a successful public
awareness campaign
V. Del Marmol (Brussels, Belgium)
02:50 PM–03:10 PM
SY1-5
Is there a skin cancer epidemic in southern America
F. Stengel (Buenos Aires, Argentina)
03:10 PM–03:30 PM
SY1-6
Skin cancer in the Middle European region
P. Arenberger (Prague, Czech Republic)
01:30 PM–03:30 PM
SY2
SYMPOSIUM
SCIENTIFIC PROGRAM
Chairs:
THU
WED
01:30 PM–03:30 PM
Wednesday, August 31, 2016
FRI
Biology of Skin Cancer Development
M. Herlyn (Philadelphia, USA)
B. Lichtenberger (Vienna, Austria)
01:30 PM–01:50 PM
SY2-1
UV and carcinogenesis – one source,
many mechanisms
T. Schwarz (Kiel, Germany)
01:50 PM–02:10 PM
SY2-2
Identification of a novel mutational signature in
cutaneous SCC associated with chronic azathioprine
exposure
G. Inman (Dundee, UK)
02:10 PM–02:30 PM
SY2-3
RG1-VLP – a chimeric virus-like particle vaccine
for prevention of HPV-associated cancers
R. Kirnbauer (Vienna, Austria)
02:30 PM–02:50 PM
SY2-4
Melanozytes – why they can give rise
to deadly tumors
M. Herlyn (Philadelphia, USA)
15
INDEX
SAT
Chairs:
POSTER
Zeremoniensaal
SY2-5
Keratinocytes and autophagy –
a role in carcinogenesis?
E. Tschachler (Vienna, Austria)
03:10 PM–03:25 PM
SY2-6
Do fibroblasts have a role in cutaneous
carcinogenesis?
B. Lichtenberger (Vienna, Austria)
01:30 PM–03:30 PM
SY3
SYMPOSIUM
Dermoscopy Part I Basics
Rittersaal
Chairs:
I. Zalaudek (Graz, Vienna)
H. Kittler (Vienna, Austria)
01:30 PM–01:50 PM
SY3-1
The good: melanocytic nevi
S. Puig (Barcelona, Spain)
01:50 PM–02:10 PM
SY3-2
The bad: melanoma
G. Argenziano (Napels, Italy)
02:10 PM–02:30 PM
SY3-3
The ugly: seborrheic keratosis
R. Hofmann-Wellenhof (Graz, Austria)
02:30 PM–02:50 PM
SY3-4
The neglected: pigmented epithelial neoplasms
I. Zalaudek (Graz, Austria)
02:50 PM–03:10 PM
SY3-5
The hidden: non-pigmented neoplasms
H. Kittler (Vienna, Austria)
03:10 PM–03:30 PM
SY3-6
The eccentric: special sites
J. Malvehy (Barcelona, Spain)
SAT
FRI
Wednesday, August 31, 2016
02:50 PM–03:10 PM
THU
WED
SCIENTIFIC PROGRAM
Scientific Program
POSTER
INDEX
03:30 PM–04:30 PM
16
COFFEE BREAK
Scientific Program
SAT1
MERCK-PFIZER ALLIANCE SYMPOSIUM
Lead:
M. Locker (Chicago, USA)
Chair:
J. Becker (Essen, Germany)
03:30 PM–03:45 PM
Welcome and introduction
J. Becker (Essen, Germany)
03:45 PM–03:55 PM
SAT1-1
Metastatic Merkel cell carcinoma:
current treatment landscape
C. Lebbé (Paris, France)
03:55 PM–04:20 PM
SAT1-2
New treatment approaches
for Merkel cell carcinoma
I. Brownell (Bethesda, USA)
SAT2
NOVARTIS SYMPOSIUM
03:30 PM–03:40 PM
SAT2-1
Welcome and introduction. What have we learned
from ASCO?
J.- J. Grob (Marseille, France)
03:40 PM–04:00 PM
SAT2-2
Primary and acquired resistance: What impact
does this have on targeted and immunotherapies?
J. Larkin (London, UK)
04:00 PM–04:20 PM
SAT2-3
How can we use the data to individualize
treatments?
R. Gutzmer (Hannover, Germany)
SAT
J.-J. Grob (Marseille, France)
INDEX
Chair:
FRI
Melanoma Changing Landscape:
Individualized Decision Making
Rittersaal
04:20 PM–04:30 PM
WED
Q&A and close
J. Becker (Essen, Germany)
THU
04:20 PM–04:30 PM
03:30 PM–04:30 PM
SCIENTIFIC PROGRAM
Current and Potential Future Treatment Options
for Merkel Cell Carcinoma
Lunch boxes will be provided.
Geheime Ratstube
POSTER
03:30 PM–04:30 PM
Wednesday, August 31, 2016
Panel discussion and Q&A
17
SCIENTIFIC PROGRAM
Scientific Program
Wednesday, August 31, 2016
04:30 PM–06:00 PM
PL1
PLENARY LECTURE
Festsaal
Chairs:
H. Pehamberger (Vienna, Austria)
C. Hoeller (Vienna, Austria)
K. Wolff (Vienna, Austria)
04:30 PM–05:15 PM
PL1-1
Immunotherapy of melanoma –
from revolution to evolution
J. Weber (New York, USA)
05:15 PM–06:00 PM
PL1-2
Targeted therapy of basal cell carcinoma –
past, present and the future
A. Sekulic (Phoenix, USA)
06:00 PM–07:00 PM
OT1
OPENING CEREMONY
Hubert Pehamberger, Congress President
Festsaal
Claus Garbe, President EADO
WED
Phili-Tango - Ensemble with members of the Vienna
Philharmonic Orchestra
FRI
Markus Mueller, Rector Medical University of Vienna
THU
Perry Robins, President Skin Cancer Foundation
07:00 PM–09:30 PM
POSTER
INDEX
SAT
Hofburg Galerie
18
OT2
GET TOGETHER
08:00 AM
Festsaal
SY4
Genetic Testing in Skin
Cancer – Methods
and Strategies
08:00 AM–08:55 AM
09:00 AM
10:00 AM
11:00 AM
SY8
Melanoma Therapy Drugs
and Trials Current Status
I – Kinase Inhibitors
09:30 AM–10:55 AM
Thursday, September 1, 2016
Zeremoniensaal
SY5
Cutaneous Lymphoma I
Biology, Epidemiology,
Genetic Research
08:00 AM–08:55 AM
Coffee Break
09:00 AM–09:30 AM
Rittersaal
SY6
Skin Cancer Centers –
What is the Worldwide
Standard?
08:00 AM–08:55 AM
SY10
BCC Epidemiology,
Biology, Genetics,
Clinical Data
09:30 AM–10:55 AM
SY9
Surgery of Skin Cancer
Primaries
09:30 AM–10:55 AM
Geheime Ratstube
SY7
Basics of (Cutaneous)
Immunology
08:00 AM–08:55 AM
SCIENTIFIC PROGRAM
Scientific Program
SAT3
LEO Pharma Breakfast
Symposium: More than
Meets the Eye
9:00 AM–10:00 AM
SY11
Skin Cancer Biology
10:00 AM–10:55 AM
PL2
Genetics
11:00 AM–12:00 PM
SY15
Sentinel Node Surgery
01:30 PM–02:50 PM
SAT5
F. Hoffmann – La Roche Vienna
Coffeehouse Symposium:
“Advanced melanoma:
Treat it personally”
03:00 PM–04:00 PM
Coffee Break
03:00 PM–04:15 PM
04:00 PM
PL3
Plenary Melanoma
04:15 PM–05:15 PM
05:00 PM
SY16
Controversies:
Is Immunotherapy the
Current Standard for Every
06:00 PM
Melanoma Patient?
05:20 PM–06:20 PM
SY17
PDT
05:20 PM–06:20 PM
WED
THU
INDEX
03:00 PM
SY14
Open Questions in
Dermatopathology
of Cutaneous Tumors
01:30 PM–02:50 PM
POSTER
02:00 PM
SY12
SY13
Melanoma Therapy Drugs Squamous Cell Carcinoma/
and Trials Current Status
AK – Epidemiology,
II – Immunotherapy
Biology, Local Therapies
01:30 PM–02:50 PM
01:30 PM–02:50 PM
FRI
01:00 PM
Lunch Break
12:00 PM–01:30 PM
SAT
SAT4
AMGEN Lunch
Symposium: Advancing
Immuno-Oncology with
an Intralesional Treatment
12:15 PM–01:15 PM
Exhibiton – Hofburg Galerie
12:00 PM
SY18
Vaccines for
Cutaneous Tumors
05:20 PM–06:20 PM
19
Scientific Program
08:00 AM–08:55 AM
SY4
SCIENTIFIC PROGRAM
J. Malvehy (Barcelona, Spain)
M. C. Fargnoli (L’Aquila, Italy)
08:00 AM–08:25 AM
SY4-1
Genetic testing in skin cancer –
from specific to abundant
G. McArthur (Melbourne, Australia)
08:25 AM–08:40 AM
SY4-2
Genetic testing in daily practice – what’s feasible?
M. C. Fargnoli (L’Aquila, Italy)
08:40 AM–08:55 AM
SY4-3
Genetic testing for skin cancer susceptibility –
did we come to an end?
I. Okamoto (Vienna, Austria)
08:00 AM–08:55 AM
SY5
SYMPOSIUM
Cutaneous Lymphoma I
Biology, Epidemiology, Genetic Research
Zeremoniensaal
Chairs:
J. Scarisbrick (Birmingham, UK)
P. Quaglino (Torino, Italy)
08:00 AM–08:13 AM
SY5-1
Pathogenetic concepts in T-cell lymphoma 2016
S. Whittaker (London, UK)
08:13 AM–08:26 AM
SY5-2
Sezary Syndrom and the EORTC translational
research projects 2016
M. H. Vermeer (Leiden, Netherlands)
08:26 AM–08:39 AM
SY5-3
Results of the cutaneous lymphoma prognostic
study (CLIPI)
J. Scarisbrick (Birmingham, UK)
08:39 AM–08:55 AM
SY5-4
The new WHO 2015 classification of cutaneous
lymphomas
R. Willemze (Leiden, Netherlands)
THU
WED
Chairs:
INDEX
SAT
FRI
SYMPOSIUM
Genetic Testing in Skin Cancer –
Methods and Strategies
Festsaal
POSTER
Thursday, September 1, 2016
20
Scientific Program
SY6
SYMPOSIUM
Skin Cancer Centers –
What is the Worldwide Standard?
Rittersaal
A.-M. Forsea (Bucharest, Romania)
P. Mohr (Buxtehude, Germany)
08:00 AM–08:15 AM
SY6-1
What should an ideal skin cancer center look like?
P. Mohr (Buxtehude, Germany)
08:15 AM–08:30 AM
SY6-2
What can we achieve in the light of
current limitations?
A.-M. Forsea (Bucharest, Romania)
08:30 AM–08:45 AM
SY6-3
How can interdisciplinary cooperation maximize
our patients benefit?
C. Hoeller (Vienna, Austria)
08:45 AM–08:55 AM
SY6-4
Panel discussion: What do we have to do
to maximize patient benefit and research output
in skin cancer centers?
08:00 AM–08:55 AM
SY7
SYMPOSIUM
WED
Chairs:
SCIENTIFIC PROGRAM
08:00 AM–08:55 AM
Thursday, September 1, 2016
Principles of cutaneous immunology
S. Grabbe (Mainz, Germany)
08:25 AM–08:40 AM
SY7-2
Trafficking of immune cells in the skin,
implications for therapy
W. Weninger (Sidney, Australia)
08:40 AM–08:55 AM
SY7-3
The emerging role of resident memory T cells
in protective immunity and inflammatory disease
T. Kupper (Boston, USA)
09:00 AM–09:30 AM
FRI
SY7-1
SAT
08:00 AM–08:25 AM
INDEX
W. Weninger (Sidney, Australia)
S. Grabbe (Mainz, Germany)
POSTER
Chairs:
THU
Basics of (Cutaneous) Immunology
Geheime Ratstube
COFFEE BREAK
21
KEYTRUDA 10 mg/kg Q3W
KEYTRUDA 10 mg/kg Q2W
Ipilimumab
0.69 (0.52–0.90)
0.63 (0.47–0.83)
HR (95% CI)
vs ipilimumab
Kaplan-Meier curve for overall survival
by treatment arm.
31%
37%
Risk reduction
vs ipilimumab
0.00358
0.00052
P value
68% 1-year estimated overall survival rate vs 58% with ipilimumaba,b
The first anti–PD-1 to demonstrate superior overall survival vs ipilimumab
START WITH KEYTRUDA
For patients with advanced melanoma
Copyright © 2015 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth,
NJ, USA. All rights reserved.
06-17-ONCO-1188131-0000. Erstellt: Juni 2016
For further Information on Posology and method of administration, Special warnings and precautions for use, Interaction with other medicinal products and other forms of interaction, Effects on ability to drive
and use machines, Undesirable effects, Overdose, Pharmacodynamic properties and Pharmacokinetic properties refer to the published summary of product characteristics.
SUMMARY OF PRODUCT CHARACTERISTICS: Name of the Medicinal Product KEYTRUDA® 50 mg powder for concentrate for solution for infusion. Qualitative and Quantitative Composition One vial of powder
contains 50 mg of pembrolizumab. After reconstitution, 1 ml of concentrate contains 25 mg of pembrolizumab. Pembrolizumab is a humanised monoclonal anti-programmed cell death-1 (PD-1) antibody (IgG4/kappa
isotype with a stabilising sequence alteration in the Fc region) produced in Chinese hamster ovary cells by recombinant DNA technology. List of excipients L-Histidine, L-Histidine hydrochloride Monohydrate,
Sucrose, Polysorbate 80 Therapeutic indications KEYTRUDA® as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Contraindications Hypersensitivity to the
active substance or to any of the excipients listed in section 6.1. Fertility, pregnancy and lactation Pregnancy There are no data on the use of pembrolizumab in pregnant women. Animal reproduction studies have
not been conducted with pembrolizumab; however, in murine models of pregnancy blockade of PD-L1 signaling has been shown to disrupt tolerance to the foetus and to result in an increased foetal loss. These
results indicate a potential risk, based on its mechanism of action, that administration of pembrolizumab during pregnancy could cause foetal harm, including increased rates of abortion or stillbirth. Human immunoglobulins G4 (IgG4) are known to cross the placental barrier and pembrolizumab is an IgG4; therefore, pembrolizumab has the potential to be transmitted from the mother to the developing foetus. Pembrolizumab
should not be used during pregnancy unless the clinical condition of the woman requires treatment with pembrolizumab. Women of childbearing potential should use effective contraception during treatment with
pembrolizumab and for at least 4 months after the last dose of pembrolizumab. Breast-feeding It is unknown whether pembrolizumab is secreted in human milk. Since it is known that antibodies can be secreted in
human milk, a risk to the newborns/infants cannot be excluded. A decision should be made whether to discontinue breast-feeding or to discontinue pembrolizumab, taking into account the benefit of breast-feeding
for the child and the benefit of pembrolizumab therapy for the woman. Fertility No clinical data are available on the possible effects of pembrolizumab on fertility. Although reproductive and developmental toxicity
studies have not been conducted with pembrolizumab, there were no notable effects in the male and female reproductive organs in monkeys based on 1-month and 6-month repeat dose toxicity studies. Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: L01XC18 Marketing Authorisation Holder Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United
Kingdom Dispensing: available only on prescription and only in pharmacies. Information as of: April 2016
Before prescribing KEYTRUDA®, please read the Prescribing Information.
Reference: 1. Robert C, Schachter J, Long GV, et al, for the KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J
Med. 2015;372(26):2521–2532.
KEYTRUDA® is indicated for the treatment of patients with unresectable or metastatic melanoma.
a
In intent-to-treat population. bMedian not reached.
PD-1=programmed death receptor-1; Q3W=every 3 weeks; Q2W=every 2 weeks; HR=hazard ratio; CI=confidence interval.
KEYNOTE-006 study design: An open-label, multicenter, randomized, controlled Phase 3 trial that included patients with unresectable or metastatic melanoma
who were naïve to ipilimumab and who had received no more than 1 prior systemic therapy. Patients with BRAF V600E mutant melanoma were not required to
have received prior BRAF inhibitor therapy. Patients were randomized (1:1:1) to receive KEYTRUDA® at a dose of 10 mg/kg every 2 (n=279) or 3 weeks (n=277) or
ipilimumab (n=278). The primary efficacy outcome measures were overall survival (OS) and progression-free survival (PFS; as assessed by Integrated Radiology
and Oncology Assessment [IRO] review using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]).1
Scientific Program
09:00 AM–10:00 AM
SAT3
SCIENTIFIC PROGRAM
Chair:
09:00 AM–09:15 AM
C. Garbe (Tuebingen, Germany)
Welcome and introduction
C. Garbe (Tuebingen, Germany)
09:15 AM–09:30 AM
SAT3-1
What lies beneath? Optimising diagnosis
of field cancerisation
I. Zalaudek (Graz, Austria)
09:30 AM–09:45 AM
SAT3-2
AK and beyond: Tailored therapy to optimise
patient outcomes
J.-J. Grob (Marseille, France)
09:45 AM–09:55 AM
SAT3-3
Panel discussion
09:55 AM–10:00 AM
WED
LEO-PHARMA BREAKFAST SYMPOSIUM
More than Meets the Eye – Treating Actinic
Keratosis (AK) and Beyond
Geheime Ratstube
09:30 AM–10:55 AM
Closing remarks and wrap up
C. Garbe (Tuebingen, Germany)
SY8
SYMPOSIUM
Melanoma Therapy Drugs and Trials Current
Status I – Kinase Inhibitors
A. Hauschild (Kiel, Germany)
FRI
09:30 AM–09:47 AM
SY8-1
Vem/Cobimetinib
G. McArthur (Melbourne, Australia)
09:47 AM–10:04 AM
SY8-2
Dabrafenib/Trametinib
A. Hauschild (Kiel, Germany)
10:04 AM–10:21 AM
SY8-3
Kinase inhibitors for N-ras mutated patients
J.-J. Grob (Marseille, France)
10:21 AM–10:38 AM
SY8-4
Kinase inhibitors for rare mutation subgroups
D. Schadendorf (Essen, Germany)
10:38 AM–10:55 AM
SY8-5
Identification of prognostic subgroups for overall
survival in patients (pts) with BRAFV600-mutated
metastatic melanoma treated with vemurafenib
± cobimetinib: a pooled exploratory analysis of
the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies
A. Hauschild (Kiel, Germany)
POSTER
Chair:
SAT
Festsaal
INDEX
THU
Thursday, September 1, 2016
24
Scientific Program
SY9
SYMPOSIUM
F. Roka (Vienna, Austria)
R. Kaufmann (Frankfurt, Germany)
09:30 AM–09:50 AM
SY9-1
Current standards for the management
of primary skin cancer lesions in Europe
R. Kaufmann (Frankfurt, Germany)
09:50 AM–10:10 AM
SY9-2
Current standards for the management
of primary skin cancer lesions in the US
J. Gershenwald (Houston, USA)
10:10 AM–10:30 AM
SY9-3
The role of mohs surgery in the management
of primary skin cancer lesions
J. Alcalay (Tel Aviv, Israel)
10:30 AM–10:55 AM
SY9-4
Managment of primary lesions of rare skin tumors
F. Roka (Vienna, Austria)
09:30 AM–10:55 AM
SY10
SYMPOSIUM
WED
Chairs:
SCIENTIFIC PROGRAM
Surgery of Skin Cancer Primaries
Rittersaal
BCC Epidemiology, Biology, Genetics,
Clinical Data
Zeremoniensaal
THU
09:30 AM–10:55 AM
Thursday, September 1, 2016
H. Hahn (Tuebingen, Germany)
R. Kunstfeld (Vienna, Austria)
09:30 AM–09:50 AM
SY10-1
Man’s most common tumor – the BCC epidemic
A. Stratigos (Athens, Greece)
09:50 AM–10:10 AM
SY10-2
Gorlin-Goltz syndrom
H. Hahn (Tuebingen, Germany)
10:10 AM–10:25 AM
SY10-3
Which open questions in BCC biology will we have
to answer in the future?
A. Sekulic (Phoenix, USA)
10:25 AM–10:40 AM
SY10-4
Use of vismodegib in the real world:
analysis of a US insurance claims database
C. Sima (San Francisco, USA)
10:40 AM–10:55 AM
SY10-5
Investigator-assessed efficacy and safety
of sonidegib in patients with locally advanced basal
cell carcinoma and metastatic basal cell carcinoma:
results of the BOLT 30-month analysis
R. Dummer (Zuerich, Switzerland)
POSTER
INDEX
SAT
FRI
Chairs:
25
Scientific Program
10:00 AM–10:55 AM
SY11
SCIENTIFIC PROGRAM
Chairs:
V. Paulitschke (Vienna, Austria)
D. Schramek (Toronto, Canada)
10:00 AM–10:20 AM
SY11-1
The role of ETS transcription factors in SCC
development
D. Schramek (Toronto, Canada)
10:20 AM–10:40 AM
SY11-2
Defining the mode of melanoma
heterogeneity and drug sensitivity by real-time
cell cycle imaging
N. Haass (Queensland, Australia)
10:40 AM–10:55 AM
SY11-3
Proteomics to reveal resistance mechanisms
beyond genetic changes
V. Paulitschke (Vienna, Austria)
11:00 AM–12:00 PM
PL2
PLENARY LECTURE
Genetics
Festsaal
Chairs:
A. Halpern (New York, USA)
C. Garbe (Tuebingen, Germany)
11:00 AM–11:30 AM
PL2-1
Genetics of Nevi – what do they tell us
about melanoma?
B. Bastian (San Francisco, USA)
11:30 AM–12:00 AM
PL2-2
Mutanome specific personalized vaccination
U. Sahin (Mainz, Germany)
SAT
FRI
THU
WED
SYMPOSIUM
Skin Cancer Biology
Geheime Ratstube
12:00 PM–01:30 PM
POSTER
INDEX
Thursday, September 1, 2016
26
LUNCH BREAK
Scientific Program
SAT4
AMGEN LUNCH SYMPOSIUM
Advancing Immuno-Oncology
with an Intralesional Treatment
Chair:
12:15 PM–12:20 PM
H. Pehamberger (Vienna, Austria)
SCIENTIFIC PROGRAM
Zeremoniensaal
Welcome and introduction
H. Pehamberger (Vienna, Austria)
12:20 PM–12:40 PM
SAT4-1
Igniting the immune response to target the tumor
C. Hoeller (Vienna, Austria)
12:40 PM–01:00 PM
SAT4-2
Talimogene laherparepvec (‘T-VEC’)*
in clinical practice
O. Michielin (Geneva, Switzerland)
01:00 PM–01:10 PM
Q&A
01:10 PM–01:15 PM
Summary and close
SY12
SYMPOSIUM
THU
01:30 PM–02:50 PM
WED
* ▼ Subject to additional monitoring. This will allow
quick identification of new safety information.
Melanoma Therapy Drugs and Trials Current
Status II – Immunotherapy
Festsaal
B. Dreno (Nantes, France)
J. Weber (Tampa, USA)
01:30 PM–01:50 PM
SY12-1
PD-1
R. Dummer (Zuerich, Switzerland)
01:50 PM–02:10 PM
SY12-2
Vaccines and cell based therapies
B. Dreno (Nantes, France)
02:10 PM–02:30 PM
SY12-3
Novel immunotherapies and combinations
J. Weber (Tampa, USA)
02:30 PM–02:40 PM
SY12-4
Efficacy and quality of life outcomes in patients
with advanced melanoma (MEL) who discontinued
treatment with nivolumab (NIVO) plus ipilimumab
(IPI) due to toxicity in a phase III trial (CheckMate 067)
D. Schadendorf (Essen, Germany)
02:40 PM–02:50 PM
SY12-5
Patterns of clinical response in talimogene
laherparepvec (T-VEC) treated patients with stage
IIIB–IVM1a melanoma in the OPTiM phase III trial
K. Harrington (London, UK)
INDEX
SAT
FRI
Chairs:
27
POSTER
12:15 PM–01:15 PM
Thursday, September 1, 2016
Scientific Program
01:30 PM–02:50 PM
SY13
SCIENTIFIC PROGRAM
WED
THU
SYMPOSIUM
Squamous Cell Carcinoma/AK-Epidemiology,
Biology, Local Therapies
Zeremoniensaal
Chairs:
A. Handisurya (Vienna, Austria)
G. Hofbauer (Zuerich, Switzerland)
01:30 PM–01:45 PM
SY13-1
From UV to SCC – insights into the biology of field
cancerization
E. Stockfleth (Bochum, Germany)
01:45 PM–02:00 PM
SY13-2
Beyond UV – viral carcinogenesis in SCC
A. Handisurya (Vienna, Austria)
02:00 PM–02:20 PM
SY13-3
Topical therapy of NMSC
R. Kunstfeld (Vienna, Austria)
02:20 PM–02:35 PM
SY13-4
Outcome evaluation of local therapies –
which endpoints show the real effect?
G. Hofbauer (Zuerich, Switzerland)
02:35 PM–02:50 PM
SY13-5
Structured expert consensus on actinic keratosis:
an up-to-date treatment algorithm
P. Calzavara-Pinton (Brescia, Italy)
01:30 PM–02:50 PM
SY14
SYMPOSIUM
Open Questions in Dermatopathology
of Cutaneous Tumors
FRI
Rittersaal
M. C. Mihm (Boston, USA)
P. Petzelbauer (Vienna, Austria)
01:30 PM–01:55 PM
SY14-1
Open questions in the histopathology of cutaneous
tumors 2016
M. C. Mihm (Boston, USA)
01:55 PM–02:13 PM
SY14-2
Desmoplastic melanoma
K. J. Busam (New York, USA)
02:13 PM–02:31 PM
SY14-3
Spitzoid melanocytic neoplasms
R. L. Barnhill (Paris, France)
02:31 PM–02:50 PM
SY14-4
Open questions and standards in the pathology
of cutaneous SCC
A. Sober (Boston, USA)
SAT
Chairs:
INDEX
POSTER
Thursday, September 1, 2016
28
Scientific Program
SY15
SYMPOSIUM
Chairs:
A. Testori (Milano, Italy)
M. Gnant (Vienna, Austria)
01:30 PM–01:50 PM
SY15-1
Sentinel node in melanoma – the evidence
behind the method
M. Ross (Houston, USA)
01:50 PM–02:10 PM
SY15-2
Lessons learned from sentinel node in breast cancer
M. Gnant (Vienna, Austria)
02:10 PM–02:30 PM
SY15-3
Do we need to perform CLND after sentinel?
C. Garbe (Tuebingen, Germany)
02:30 PM–02:50 PM
SY15-4
Sentinel node in skin cancer beyond melanoma
J. Gershenwald (Houston, USA)
03:00 PM–04:15 PM
F. HOFFMANN-LA ROCHE LTD.
VIENNA COFFEEHOUSE SYMPOSIUM
J. Larkin (London, UK) 03:00 PM–03:15 PM
SAT5-1
The current treatment landscape in advanced
melanoma”
J. Larkin (London, UK) 03:15 PM–03:55 PM
SAT5-2
Summary and close
J. Larkin (London, UK)
INDEX
Chair:
SAT
Advanced melanoma: Treat it personally
Optimising outcomes with targeted therapies in
advanced melanoma in your clinical practice
Zeremoniensaal
THU
SAT5
WED
COFFEE BREAK
POSTER
03:00 PM–04:00 PM
SCIENTIFIC PROGRAM
Setinel Node Surgery
Geheime Ratstube
FRI
01:30 PM–02:50 PM
Thursday, September 1, 2016
29
Scientific Program
04:15 PM–05:15 PM
PL3
PLENARY LECTURE
Melanoma
Festsaal
SCIENTIFIC PROGRAM
Thursday, September 1, 2016
Chairs:
D. Schadendorf (Essen, Germany)
G. McArthur (Brisbane, Australia)
04:15 PM–04:45 PM
PL3-1
Combination therapies for skin cancer –
where do we go?
C. Blank (Amsterdam, Netherlands)
04:45 PM–05:15 PM
PL3-2
Biomarkers for melanoma treatment –
how will they impact our treatment decisions?
O. Michielin (Lausanne, Switzerland)
05:20 PM–06:20 PM
SY16
SYMPOSIUM
Controversies: Is Immunotherapy the Current
Standard for Every Melanoma Patient? Pro/Con
R. Dummer (Zuerich, Switzerland)
P. Arenberger (Prague, Czech Republic)
05:20 PM–05:40 PM
SY16-1
Pro
J. Larkin (London, UK)
THU
05:40 PM–06:00 PM
SY16-2
Contra
O. Michielin (Lausanne, Switzerland)
06:00 PM–06:20 PM
05:20 PM–06:20 PM
POSTER
Discussion with the audience
SY17
SYMPOSIUM
PDT
Zeremoniensaal
Chairs:
S. Radakovic (Vienna, Austria)
R.-M. Szeimies (Recklinghausen, Germany)
05:20 PM–05:35 PM
SY17-1
Topical photodynamic therapy in dermatology –
how does it work?
L. Braathen (Bern, Switzerland)
05:35 PM–05:50 PM
SY17-2
PDT for skin cancer – what should we treat
and what not?
E. Sotiriou (Thessaloniki, Greece)
05:50 PM–06:05 PM
SY17-3
Day-light PDT – a major breakthrough
in dermatological PDT?
R.-M. Szeimies (Recklinghausen, Germany)
06:05 PM–06:20 PM
SY17-4
PDT-associated pain – are there means for relief?
S. Radakovic (Vienna, Austria)
INDEX
SAT
WED
Chairs:
FRI
Festsaal
30
Read JDDG
on the Go
App available for iPad®, iPhone® and iPod Touch®
Experience an entirely new
browsing and reading experience
• Convenient access to articles anytime, anywhere
• Quick navigation to any section of the app
• Immediate access to new content
• Select keywords for tailored content alerts
• Downloadissuestoreadoffline,orshareimportantarticles
• Enhanced search across all downloaded content
Scan the QR code,
or visit your App Store®
online to download the app today
239807
• Sync your favorite app content across devices via iCloud®
Scientific Program
05:20 PM–06:20 PM
SY18
SCIENTIFIC PROGRAM
SYMPOSIUM
Vaccines for Cutaneous Tumors
Rittersaal
Chairs:
U. Sahin (Mainz, Germany)
G. Schuler (Erlangen, Germany)
05:20 PM–05:40 PM
SY18-1
Vaccines for melanoma – time for a comeback?
G. Schuler (Erlangen, Germany)
05:40 PM–06:00 PM
SY18-2
Oncolytic viruses: vehicles for endogenus
vaccination?
R. Andtbacka (Salt Lake City, USA)
06:00 PM–06:20 PM
SY18-3
RNA based mutanome specific vaccines –
a true personalized therapy
U. Sahin (Mainz, Germany)
05:20 PM–06:20 PM
PW1
POSTERWALK
Marmorsaal/
Antekammer
POSTER
INDEX
SAT
FRI
THU
WED
Thursday, September 1, 2016
32
Melanoma
P001- P099
Late-Breaking P206 - P219
Scientific Program
09:00 AM
10:00 AM
11:00 AM
Festsaal
SY19
Controversies: Is there
a Dysplastic Nevus?
08:00 AM–08:55 AM
SY22
Neo-adjuvant Treatment
in Skin Cancer Patients
09:00 AM–10:30 AM
Zeremoniensaal
Rittersaal
SY20
SY21
Chemotherapy of Skin
Cutaneous Side Effects
Cancers – Does it Still
of Oncological Drugs
Have a Role in Our
08:00 AM–08:55 AM
Algorithms?
08:00 AM–08:55 AM
SY23
SY24
Cutaneous Lymphoma II – Genetics of Skin Cancer
Therapy Update
09:00 AM–10:30 AM
09:00 AM–10:30 AM
Coffee Break
10:30 AM–11:00 AM
Geheime Ratstube
FC1
Free Communications:
Melanoma
08:00 AM–08:55 AM
SCIENTIFIC PROGRAM
08:00 AM
Friday, September 2, 2016
SY25
Dermosocopy II Experts
09:00 AM–10:30 AM
PL4
Cutaneous Lymphoma,
New Drugs
11:00 AM–12:00 PM
04:00 PM
05:00 PM
SY30
UV-Protection,
Vitamin D and
Photoaging
04:05 PM–05:25 PM
SY34
Controversies: Sentinel
Node and Completion
06:00 PM
Lymph Node Dissection –
Standard of Care?
05:30 PM–06:30 PM
08:00 PM
SY35
Skin Cancer in Special
Patient Subgroups
05:30 PM–06:30 PM
WED
THU
SY29
What’s a Drugs Value?
01:30 PM–02:50 PM
FRI
03:00 PM
SY28
Tumor Immunology
01:30 PM–02:50 PM
Coffee Break
03:00 PM–04:00 PM
SY32
Smart Sequencing or
Combination Therapy –
in Search for the Best
Strategy
04:05 PM–05:25 PM
SY36
Locoregional Therapy of
Melanoma Metastases
05:30 PM–06:30 PM
SAT
SY26
How to Overcome Drug
Resistance
01:30 PM–02:50 PM
INDEX
02:00 PM
Lunch Break/Exhibition
12:00 PM–01:15 PM
SY33
Orphan Skin Cancer
– Epidemiology,
Histopathology, Biology,
Therapy
04:05 PM–05:25 PM
SY37
Psychodermatooncology
05:30 PM–06:30 PM
POSTER
01:00 PM
SAT6
Lunch Symposium
Bristol-Myers Squibb:
Immuno Oncology for
Melanoma: What’s new?
12:15 AM–01:15 PM
SY27
Systemic Treatment
of Non-Melanoma
Skin Cancer
01:30 PM–02:50 PM
SAT7
MSD Vienna Coffeehouse
Symposium:
Great Debates of ImmunoOncology Therapies
in Advanced Melanoma
03:00 PM–04:00 PM
SY31
Melanoma Surgery Lymph
Nodes to Distant
04:05 PM–05:25 PM
Exhibiton – Hofburg Galerie
12:00 PM
OT3
Networking Evening (Heuriger)
08:00 PM
33
CURRENTLY ENROLLING: JAVELIN Merkel 200
(First-line Cohort)
A Phase 2, open-label, multicenter trial to investigate the clinical
activity and safety of avelumab* (MSB0010718C) in subjects with
metastatic Merkel cell carcinoma
FOR MORE INFORMATION: www.clinicaltrials.gov (NCT02155647)
The JAVELIN clinical trial program studies avelumab in Phases 1-3, both as monotherapy
and in combination with other agents.
The program includes diseases with large patient populations as well as rare diseases
with high unmet needs.
Trials are currently enrolling patients with†:
• Merkel Cell Carcinoma (MCC)
• Hodgkin’s lymphoma
• Renal Cell Carcinoma (RCC)
• Melanoma
• Non-Small Cell Lung Cancer (NSCLC)
• Squamous Cell Carcinoma of the Head and Neck (SCCHN)
• Ovarian cancer
• Adenocarcinoma of the stomach or of the gastroesophageal junction
• Urothelial cancer
Avelumab is an investigational agent.
*Avelumab is the nonproprietary name for the anti-PD-L1 monoclonal antibody (MSB0010718C).
†
NCT02155647, NCT02603419, NCT02684006, NCT02493751, NCT02554812, NCT02395172, NCT02576574,
NCT02584634, NCT02580058, NCT02625610, NCT02625623, NCT01772004, NCT02603432
This information is current as of June 2016.
June 2016
US-AVL-0116-0004(1)
Scientific Program
SY19
SYMPOSIUM
Chairs:
P. Tschandl (Vienna, Austria)
C. Hoeller (Vienna, Austria)
08:00 AM–08:20 AM
SY19-1
Pro
B. Bastian (San Francisco, USA)
08:20 AM–08:40 AM
SY19-2
Contra
H. Kittler (Vienna, Austria)
08:40 AM–08:55 AM
Discussion with the audience
SY20
SYMPOSIUM
SY20-1
Chemotherapy for melanoma –
last resort or still an option?
P. Lorigan (Manchester, UK)
08:13 AM–08:26 AM
SY20-2
Chemotherapy for metastatic SCC
R. Gutzmer (Hanover, Germany)
08:26 AM–08:39 AM
SY20-3
Chemotherapy for cutaneous lymphomas
L. Geskin (New York, USA)
08:39 AM–08:55 AM
SY20-4
Chemotherapy in the treatment of orphan
skin cancers
R. Loewe (Vienna, Austria)
08:00 AM–08:55 AM
SY21
SYMPOSIUM
THU
08:00 AM–08:13 AM
FRI
P. Lorigan (Manchester, UK)
R. Gutzmer (Hanover, Germany)
SAT
Chairs:
WED
Chemotherapy of Skin Cancers –
Does It Still Have a Role in Our Algorithms?
Zeremoniensaal
INDEX
08:00 AM–08:55 AM
SCIENTIFIC PROGRAM
Controversies: Is There a Dysplastic Nevus?
Festsaal
POSTER
08:00 AM–08:55 AM
Friday, September 2, 2016
Cutaneous Side Effects of Oncological Drugs
Rittersaal
Chairs:
C. Lebbé (Paris, France)
V. Sibaud (Toulouse, France)
08:00 AM–08:30 AM
SY21-1
Cutaneous side effects of drugs in general
oncology
V. Sibaud (Toulouse, France)
08:30 AM–08:55 AM
SY21-2
Cutaneous side effects of novel PI3K inhibitors
in mono- and combination-therapy
K. Schindler (Vienna, Austria)
35
Scientific Program
08:00 AM–08:55 AM
FC1
SCIENTIFIC PROGRAM
WED
P. Petzelbauer (Vienna, Austria)
M. Herlyn (Philadelphia, USA)
08:00 AM–08:12 AM
FC1-1
The role of the lymphovasculature during
skin cancer development
P. Petzelbauer (Vienna, Austria)
08:12 AM–08:24 AM
FC1-2
Wnt signalling as a metabolic regulator
in melanoma cells
V. Sherwood (Dundee, UK)
08:24 AM–08:36 AM
FC1-3
Modeling Wnt secretion in cutaneous squamous
cell carcinoma
K. I. Kober (Heidelberg, Germany)
08:36 AM–08:48 AM
FC1-4
Upregulated sonic hedgehog activity drives
the development of congenital nevi
A. Chitsazan (Herston/Brisbane, Australia)
08:48 AM–08:55 AM
FC1-5
Understanding benign T-cell infiltration in mycosis
fungoides: Malignant clones are not lone
P. A. Vieyra-Garcia (Graz/Boston, Austria, MA; USA)
09:00 AM–10:30 AM
SY22
SYMPOSIUM
FRI
THU
Chairs:
Neo-adjuvant Treatment in Skin
Cancer Patients
Festsaal
Chairs:
H. Pehamberger (Vienna, Austria)
H. Gogas (Athens, Greece)
09:00 AM–09:20 AM
SY22-1
From adjuvant to neo-adjuvant treatment
in skin cancers – time to change the paradigm?
J.-J. Grob (Marseille, France)
09:20 AM–09:40 AM
SY22-2
Can biomarkers help us to select patients
for neo‑adjuvant treatment?
H. Gogas (Athens, Greece)
09:40 AM–10:00 AM
SY22-3
Neoadjuvant treatment in melanoma –
a useful strategy?
J. Kirkwood (Pittsburgh, USA)
10:00 AM–10:30 AM
SY22-4
Surgical strategies to maximize the outcome
of neo-adjuvant treatment
A. Testori (Milano, Italy)
SAT
INDEX
FREE COMMUNICATIONS
Melanoma
Geheime Ratstube
POSTER
Friday, September 2, 2016
36
Scientific Program
SY23
SYMPOSIUM
09:00 AM–09:15 AM
SY23-1
EORTC treatment guidelines 2015
F. Trautinger (St. Poelten, Austria)
09:15 AM–09:30 AM
SY23-2
Use of alemtuzumab and radiation therapy
in CTCL
R. A. Clark (Boston, USA)
09:30 AM–09:45 AM
SY23-3
Mogamolizumab in CTCL
M. Duvic (Houston, USA)
09:45 AM–10:00 AM
SY23-4
Treatment update on b-cell lymphomas
M. Bagot (Paris, France)
10:00 AM–10:15AM
SY23-5
Brentuximab vendotin in CTCL
R. Stadler (Minden, Germany)
10:15 AM–10:30 AM
SY23-6
Photopheresis in CTCL
R. Knobler (Vienna, Austria)
09:00 AM–10:30 AM
SY24
SYMPOSIUM
WED
L. Geskin ( New York, USA)
L. Papadavid (Ort, Greece)
THU
Chairs:
SCIENTIFIC PROGRAM
Cutaneous Lymphoma II – Therapy Update
Zeremoniensaal
09:00 AM–09:20 AM
SY24-1
Genetics of melanocytic tumors –
from benign to malignant
B. Bastian (San Francisco, USA)
09:20 AM–09:40 AM
SY24-2
Genetic background and UV – how
do they cooperate to form skin cancer?
N. Hayward (Brisbane, Australia)
09:40 AM–10:00 AM
SY24-3
Acquired mutations in melanoma,
B-raf and beyond
G. McArthur (Brisbane, Australia)
10:00 AM–10:30 AM
SY24-4
The role of telomers in skin tumors
R. Kumar (Heidelberg, Germany)
SAT
I. Okamoto (Vienna, Austria)
B. Bastian (San Francisco, USA)
INDEX
Chairs:
FRI
Genetics of Skin Cancer
Rittersaal
POSTER
09:00 AM–10:30 AM
Friday, September 2, 2016
37
Scientific Program
09:00 AM–10:30 AM
SY25
SCIENTIFIC PROGRAM
WED
THU
Chairs:
W. Stolz (Munich, Germany)
C. Rosendahl (Brisbane, Australia)
09:00 AM–09:15 AM
SY25-1
Challenging cases
W. Stolz (Munich, Germany)
09:15 AM–09:30 AM
SY25-2
Twin cases
P. Tschandl (Vienna, Austria)
09:30 AM–09:45 AM
SY25-3
Nail cases
L. Thomas (Lyon, France)
09:45 AM–10:00 AM
SY25-4
Non-pigmented cases
C. Rosendahl (Brisbane, Australia)
10:00 AM–10:15 AM
SY25-5
Unusual cases
H. Kittler (Vienna, Austria)
10:15 AM–10:30 AM
SY25-6
Challenging high risk patients
S. Puig (Barcelona, Spain)
10:30 AM–11:00 AM
11:00 AM–12:00 PM
COFFEE BREAK
PL4
PLENARY LECTURE
Cutaneous Lymphoma, New Drugs
Festsaal
Chairs:
R. Knobler (Vienna, Austria)
J. Kirkwood (Pittsburgh, USA)
11:00 AM–11:30 AM
PL4-1
New insights in understanding T-cell biology
in cutaneous lymphoma
R. Clark (Boston, USA)
11:30 AM–12:00 PM
PL4-2
New therapies – price vs. value – can we afford it?
J. Larkin (London, UK)
INDEX
SAT
FRI
SYMPOSIUM
Dermosocopy II Experts
Geheime Ratstube
POSTER
Friday, September 2, 2016
12:00 PM–01:15 PM
38
LUNCH BREAK
Actinic Keratosis
Editors:
H. Peter Soyer
Tarl W. Prow
Gregor B.E. Jemec
Current Problems in Dermatology, Vol. 46
Actinic Kreatosis
VIII + 154 p., 33 fig., 29 in color, 4 tab., 2015
CHF 189.00 / EUR 177.00 / USD 222.00
(hard cover or online*)
ISBN 978–3–318–02762–4
e
th th
at oo
e b
bl ss
la e
ai epr
Av is
W
Extraordinary insights into an
ordinary pathology
Current Problems in Dermatology
Editors: P. Itin, G.B.E. Jemec
Vol. 46
Actinic
Keratosis
Editors
H.P. Soyer
T.W. Prow
G.B.E. Jemec
Renowned experts present the
latest knowledge
Skin Barrier
Function
Current Problems in Dermatology
Editors: P. Itin, G.B.E. Jemec
Vol. 49
Skin Barrier
Function
Editor
Editor: Tove Agner
Current Problems in Dermatology, Vol. 49
Skin Barrier Function
VIII + 164 p., 26 fig., 6 in color, 14 tab., 2016
CHF 179.00 / EUR 167.00 / USD 211.00
(hard cover or online*)
ISBN 978–3–318–05585–6
*online prices for personal customers
Prices subject to change, VAT not included
EUR price for eurozone countries,
USD price for USA and Latin America only
Order at:
www.karger.com/cupde
[email protected]
KI16406
T. Agner
25
O
S
S
E
R
NG
TH
C
V
D
A
E
GY
OLO
RE
VENE
16
0
2
R
D
Y OF
TOBE
C
ADEM
C
O
A
- 2 , VIENNA
PEAN
R
E
EURO
B
EM RIA CENTER TRIA
T
P
E
AUST
28 S
, AUa2S016.org
A
N
VIEwN.eadvvienn
ND
GY A
TOLO
ERMA
ww
Join us
in Vien
n
for the TaH
25
EADV
Congre
ss
Scientific Program
SAT6
BRISTOL-MYERS SQUIBB LUNCH SYMPOSIUM
Immuno Oncology for Melanoma:
What’s New?
Chair:
Welcome and introduction
C. Hoeller (Vienna, Austria)
12:20 PM–12:30 PM
SAT6-1
Melanoma 2016: Recent data and clinical
implications
J. Weber (New York, USA)
12:30 PM-12:40 PM
SAT6-2
The principles and practice of immuno-oncology
adverse event management
J. Larkin (London, UK)
12:40 PM–01:10 PM
SAT6-3
Expert insights into patient management
Melanoma case presentations:
C. Lebbé (Paris, France)
Interactive discussion moderated by:
C. Hoeller (Vienna Austria)
SY26
THU
SYMPOSIUM
Chairs:
C. Blank (Amsterdam, Netherlands)
P. Ascierto (Napels, Italy)
01:30 PM–01:50 PM
SY26-1
Update on resistance mechanisms against
targeted drugs
A. Roesch (Essen, Germany)
01:50 PM–02:10 PM
SY26-2
The role of epigenetic adaptations in the escape
from BRAF inhibitor therapy
K. Smalley (Tampa, USA)
02:10 PM–02:30 PM
SY26-3
Resistance against check-point inhibitors –
what are the mechanisms?
P. Ascierto (Napels, Italy)
02:30 PM–02:50 PM
SY26-4
Strategies to overcome drug resistance
in melanoma
C. Blank (Amsterdam, Netherlands)
SAT
How to Overcome Drug Resistance
Festsaal
INDEX
01:30 PM–02:50 PM
Summary and close
C. Hoeller (Vienna, Austria)
FRI
01:10 PM–01:15 PM
WED
12:15 PM–12:20 PM
C. Hoeller (Vienna, Austria)
SCIENTIFIC PROGRAM
Zeremoniensaal
POSTER
12:15 PM–01:15 PM
Friday, September 2, 2016
41
Scientific Program
01:30 PM–02:50 PM
SY27
SYMPOSIUM
Systemic Treatment of Non-Melanoma
Skin Cancer
Zeremoniensaal
Chairs:
A. Stratigos (Athens, Greece)
M. Bylaitė-Bučinskienė (Vilnius, Lithuania)
01:30 PM–01:50 PM
SY27-1
Systemic drugs to prevent non-melanoma
skin cancer
A. Stratigos (Athens, Greece)
01:50 PM–02:10 PM
SY27-2
Systemic treatment of BCC – current status
and future directions
R. Kunstfeld (Vienna, Austria)
02:10 PM–02:30 PM
SY27-3
Systemic treatment of metastatic SCC –
what’s new?
J. Hofbauer (Zuerich, Switzerland)
02:30 PM–02:50 PM
SY27-4
Systemic treatment of cutaneous sarcomas
R. Gutzmer (Hanover, Germany)
01:30 PM–02:50 PM
SY28
SYMPOSIUM
Tumor Immunology
T. Tueting (Bonn, Germany)
G. Stingl (Vienna, Austria)
01:30 PM–01:50 PM
SY28-1
How tumors escape immune surveillance
T. Tueting (Bonn, Austria)
01:50 PM–02:10 PM
SY28-2
Killing or control – what defines an effective tumor
immune-response?
W. Weninger (Sidney, Australia)
02:10 PM–02:30 PM
SY28-3
The role of dendritic cells in tumor immunology
G. Stingl (Vienna, Austria)
02:30 PM–02:50 PM
SY28-4
Inhibition of the novel immune
checkpoint CEACAM1 to enhance anti-tumor
immunological activity
G. Markel (Tel Aviv, Israel)
POSTER
FRI
Chairs:
SAT
Rittersaal
INDEX
THU
WED
SCIENTIFIC PROGRAM
Friday, September 2, 2016
42
Scientific Program
SY29
SYMPOSIUM
Chairs:
H. Pehamberger (Vienna, Austria)
M. Binder (Vienna, Austria)
01:30 PM–01:45 PM
SY29-1
How do we define value in cancer care
J. Kirkwood (Pittsburgh, USA)
01:45 PM–02:00 PM
SY29-2
The cost impact of modern skin cancer
treatments – the European view
M. Binder (Vienna, Austria)
02:00 PM–02:15 PM
SY29-3
The cost impact of modern skin cancer
treatments – the US view
S. Agarwala (New York, USA)
02:15 PM–02:30 PM
SY29-4
Solutions in the adaption to new cancer
treatment paradigms
C. Zielinski (Vienna, Austria)
Panel discussion with audience
03:00 PM–04:00 PM
COFFEE BREAK
THU
02:30 PM–02:50 PM
SCIENTIFIC PROGRAM
What’s a Drug’s Value?
Geheime Ratstube
WED
01:30 PM–02:50 PM
Friday, September 2, 2016
MSD VIENNA COFFEEHOUSE SYMPOSIUM
Great Debates of Immuno-Oncology Therapies
in Advanced Melanoma
Chair:
Welcome and introduction
A. Hauschild (Kiel, Germany)
03:05 PM–03:20 PM
SAT7-1
Clinical data update on immune checkpoint
inhibitors
A. Hauschild (Kiel, Germany)
03:20 PM–03:30 PM
SAT7-2
Debate I: Combination immunotherapy
vs single‑agent immunotherapy: does
combination immunotherapy outweigh
monotherapy in 1L settings?
S. Agarwala (New York, USA)
03:30 PM–03:40 PM
SAT7-3
Debate II: Targeted therapy vs immunotherapy:
is targeted therapy the most appropriate 1L
treatment choice for BRAF-mutated patients?
C. Blank (Amsterdam, Netherlands)
INDEX
03:00 PM–03:05 PM
A. Hauschild (Kiel, Germany)
SAT
Zeremoniensaal
FRI
SAT7
POSTER
03:00 PM–04:00 PM
43
Scientific Program
SAT7-4
03:50 PM–04:00 PM
04:05 PM–05:25 PM
Debate III: Novel combinations: should the
novel immunotherapy combination regimens
be built on the 1L clinical profile established
by the ipilimumab + nivolumab combination?
J. Weber (New York, USA)
Q&A Session and close
SY30
SYMPOSIUM
UV-Protection, Vitamin D and Photoaging
Chairs:
H. Hoenigsmann (Vienna, Austria)
H. Lim (Detroit, USA)
04:05 PM–04:27 PM
SY30-1
UV – the good and the bad sides
S. Beissert (Leipzig, Germany)
04:27 PM–04:49 PM
SY30-2
Sun protection – how does it work
and does it work?
H. Hoenigsmann (Vienna, Austria)
WED
04:49 PM–05:11 PM
SY30-3
Vitamin-D – what you always wanted to know
H. Lim (Detroit, USA)
THU
Festsaal
05:11 PM–05:25 PM
SY30-4
Laser therapy of photoaging
D. Sarnoff (New York, USA)
FRI
SCIENTIFIC PROGRAM
03:40 PM–03:50 PM
Friday, September 2, 2016
04:05 PM–05:25 PM
SY31
SYMPOSIUM
Melanoma Surgery: Lymph Nodes
to Distant
POSTER
INDEX
SAT
Zermoniensaal
Chairs:
M. Ross (Houston, USA)
R. Andtbacka (Salt Lake City, USA)
04:05 PM–04:25 PM
SY31-1
Lymph node surgery in melanoma patients
J. Gershenwald (Houston, USA)
04:25 PM–04:45 PM
SY31-2
Surgery of distant metastases – when and how
A. Testori (Milan, Italy)
04:45 PM–05:05 PM
SY31-3
Cutaneous metastases – when to excise
and when to treat
R. Andtbacka (Salt Lake City, USA)
05:05 PM–05:25 PM
SY31-4
How does the role of surgery in melanoma change
in the current therapeutic landscape
M. Ross (Houston, USA)
44
Scientific Program
SY32
SYMPOSIUM
Smart Sequencing or Combination Therapy –
in Search for the Best Strategy
Rittersaal
N. Haass (Queensland, Australia)
K. Smalley (Tampa, USA)
04:05 PM–04:25 PM
SY32-1
Sequencing in melanoma – which options
do we have?
C. Blank (Amsterdam, Netherlands)
04:25 PM–04:45 PM
SY32-2
How can we make the best use of kinase inhibitors
in melanoma?
A. Hauschild (Kiel, Germany)
04:45 PM–05:05 PM
SY32-3
How can we make the best use of immunotherapy
in melanoma?
P. Ascierto (Napels, Italy)
05:05 PM–05:25 PM
SY32-4
How can we combine new drugs
with local treatment strategies
R. Dummer (Zuerich, Switzerland)
04:05 PM–05:25 PM
SY33
SYMPOSIUM
THU
WED
Chairs:
SY33-1
What is “orphan skin cancer”
R. Loewe (Vienna, Austria)
04:20 PM–04:40 PM
SY33-2
Orphan drugs for orphan skin cancer
J. Becker (Essen, Germany)
04:40 PM – 05:00 PM
SY33-3
Surgical therapy of cutaneous sarcomas
P. Funovics (Vienna, Austria)
05:00 PM–05:15 PM
SY33-4
Dermatofibrosarcoma protuberans –
current guidelines
P. Saiag (Paris, France)
05:15 PM–05:25 PM
SY33-5
Genomic and immune heterogeneity
in non‑viral merkel cell carcinoma
R. Tothill (Melbourne, Australia)
SAT
04:05 PM–04:20 PM
INDEX
R. Loewe (Vienna, Austria)
P. Saiag (Paris, France)
POSTER
Chairs:
FRI
Orphan Skin Cancer – Epidemiology,
Histopathology, Biology, Therapy
Geheime Ratstube
SCIENTIFIC PROGRAM
04:05 PM–05:25 PM
Friday, September 2, 2016
45
Scientific Program
05:30 PM–06:30 PM
SY34
SCIENTIFIC PROGRAM
SYMPOSIUM
Controversies: Sentinel Node and Completion
Lymph Node Dissection – Standard of Care?
Festsaal
Chairs:
H. Pehamberger (Vienna, Austria)
J. Gershenwald (Houston, USA)
05:30 PM–06:00 PM
SY34-1
Pro
M. Ross (Houston, USA)
06:00 PM–06:30 PM
SY34-2
Contra
C. Garbe (Tuebingen, Germany)
Discussion with the audience
05:30 PM–06:30 PM
SY35
SYMPOSIUM
Skin Cancer in Special
Patient Subgroups
Zeremoniensaal
A. Geusau (Vienna, Austria)
J. Olah (Szeged, Hungary)
05:30 PM–05:50 PM
SY35-1
Epidemiology and prevention of skin cancer
in immunosuppressed patients
A. Geusau (Vienna, Austria)
05:50 PM–06:10 PM
SY35-2
Treatment of skin cancer in immune-supressed
patients – different from immunocompetent
patients?
C. Lebbé (Paris, France)
06:10 PM–06:30 PM
SY35-3
Skin cancer in patients previously irradiated –
a frequent event?
A. Geller (Boston, USA)
FRI
THU
WED
Chairs:
POSTER
INDEX
SAT
Friday, September 2, 2016
46
Scientific Program
SY36
SYMPOSIUM
Locoregional Therapy of Melanoma
Metastases
Rittersaal
Chairs:
L. Kandolf-Sekulovic (Belgrade, Serbia)
S. Agarwala (Bethlehem, USA)
05:30 PM–06:50 PM
SY36-1
Therapies for patients with locoregional
metastases – What are our current options?
R. Dummer (Zuerich, Switzerland)
05:50 PM–06:10 PM
SY36-2
Intralesional therapies – what’s around the corner?
S. Agarwala (Bethlehem, USA)
06:10 PM–06:30 PM
SY36-3
Intralesional and systemic therapies –
Which combinations are most promising?
R. Andtbacka (Salt Lake City, USA)
05:30 PM–06:30 PM
SY37
SYMPOSIUM
SY37-1
Breaking bad news to cancer patients –
the do’s and the dont’s
P. Schuetzl (Vienna, Austria)
06:00 PM–06:30 PM
SY37-2
Strategies to support our patients beyond
Pharmacotherapy – what everyone can do
E. Lehner- Baumgartner (Vienna, Austria)
08:00 PM
OT3
NETWORKING EVENING
THU
05:30 PM– 06:00 PM
FRI
E. Lehner-Baumgartner (Vienna, Austria)
INDEX
SAT
Chair:
WED
Psychodermatooncology
Geheime Ratstube
SCIENTIFIC PROGRAM
05:30 PM–06:30 PM
Friday, September 2, 2016
POSTER
Heuriger Welser
47
Immuno-Oncology
12:00 PM
SY40
Predictive Biomarkers
in Melanoma
10:30 AM–11:30 AM
PL5
Future Targets and
Combinations
11:35 AM–12:05 PM
OT4
Closing Ceremony
12:05 PM–12:30 PM
SY42
Brain Metastases
10:30 AM–11:30 AM
SCIENTIFIC PROGRAM
11:00 AM
WED
10:00 AM
THU
FC2
A. Steiner,
H. Pehamberger
09:00 AM–10:00 AM
Coffee Break
10:00 AM–10:30 AM
SY41
New Methods in Early
Detection of Skin Cancer
10:30 AM–11:30 AM
Geheime Ratstube
FRI
FC3
C. Posch, C. Hoeller
09:00 AM–10:00 AM
Rittersaal
SAT
Zeremoniensaal
SY39
Current Standard
of Imaging Methods
for Skin Cancer Patients
08:00 AM–09:00 AM
INDEX
09:00 AM
Festsaal
SY38
Side Effects of Systemic
Skin Cancer Therapies
08:00 AM–09:00 AM
POSTER
08:00 AM
Saturday, September 3, 2016
Exhibiton – Hofburg Galerie
Scientific Program
49
Scientific Program
08:00 AM–09:00 AM
SY38
SCIENTIFIC PROGRAM
WED
Chairs:
K. Schindler (Vienna, Austria)
C. Loquai (Mainz, Germany)
08:00 AM–08:15 AM
SY38-1
Side effects of systemic therapies for NMSC
C. Loquai (Mainz, Germany)
08:15 AM–08:30 AM
SY38-2
Side effects of targeted therapies for metastatic
melanoma (BRAF/MEK)
C. Lebbé (Paris, France)
08:30 AM–08:45 AM
SY38-3
Side effects of immunotherapies for metastatic
melanoma
K. Schindler (Vienna, Austria)
08:45 AM–09:00 AM
SY38-4
Discussion: How will future combinations impact
side effect management?
08:00 AM–09:00 AM
SY39
SYMPOSIUM
Current Standard of Imaging Methods
for Skin Cancer Patients
Zermoniensaal
THU
FRI
SAT
INDEX
SYMPOSIUM
Side Effects of Systemic Skin Cancer Therapies
Festsaal
POSTER
Saturday, September 3, 2016
Chairs:
N. Schwenzer (Tuebingen, Germany)
M. Mayerhoefer (Vienna, Austria)
08:00 AM–08:15 AM
SY39-1
Whole-body staging of melanoma
N. Schwenzer (Tuebingen, Germany)
08:15 AM–08:30 AM
SY39-2
Treatment response assessment in melanoma
M. Mayerhoefer (Vienna, Austria)
08:30 AM–09:00 AM
SY39-3
Radiopharmaceuticals for molecular imaging
of melanoma
M. Mitterhauser (Vienna, Austria)
W. Wadsak (Vienna, Austria)
08:00 AM–09:00 AM
PW2
POSTERWALK
Marmorsaal/
Antekammer
50
Non-Melanoma Skin Cancer
Cutaneous Lymphoma
Orphan Skin Cancer
Skin Cancer in General
P100 - P169
P170 - P190
P191 - P196
P197 - P205
Scientific Program
FC2
FREE COMMUNICATIONS
09:12 AM–09:24 AM
FC2-2
Impact of adjuvant immunotherapy on survival
of patients with resected stage III melanoma
diagnosed in 2003–2011 in the US
S. Jang (Fairfax, VA, USA)
09:24 AM–09:36 AM
FC2-3
Treatment efficacy with electrochemotherapy:
a multi-institutional prospective observational
study on 376 patients with superficial tumors
L. G. Campana (Padova, Italy)
09:36 AM–09:48 AM
FC2-4
Sun protection after melanoma diagnosis
improves survival
C. Mueller, (Vienna, Austria)
09:48 AM–10:00 AM
FC2-5
Evaluation of 5-fluorouracil 0.5%/salicylic acid 10%
in the field-directed treatment of actinic keratosis:
a phase III, randomised, vehicle-controlled trial
E. Stockfleth (Bochum, Germany)
09:00 AM–10:00 AM
FC3
FREE COMMUNICATIONS
09:00 AM–09:12 AM
FC3-1
Can Melanoma treatment be guided by a panel of
predictive and prognostic MicroRNA biomarkers?
M. Stark (Brisbane, Australia)
09:12 AM–09:24 AM
FC3-2
Response patterns to MEK inhibition, but not NRAS
mutation status predict the efficacy of combined
MEK/CDK4,6 targeting in melanoma
C. Posch (Vienna, Austria)
09:24 AM–09:36 AM
FC3-3
Incidence, course, and management of toxicities
associated with cobimetinib combined
with vemurafenib in the cobrim study:
an updated analysis
B. Dreno (Nantes, France)
09:36 AM–09:48 AM
FC3-4
Basal cell carcinoma cancer stem cells promote
immune evasion
G. Patel (Cardiff, UK)
51
INDEX
SAT
C. Posch (Vienna, Austria)
C. Hoeller (Vienna, Austria)
Festsaal
WED
Inverse association between atopy and melanoma:
a case-control study
V. Marasigan (Leuven, Belgium)
THU
FC2-1
FRI
09:00 AM–09:12 AM
SCIENTIFIC PROGRAM
A. Steiner (Vienna, Austria)
H. Pehamberger (Vienna, Austria)
Zeremoniensaal
POSTER
09:00 AM–10:00 AM
Saturday, September 3, 2016
Scientific Program
FC3-5
10:00 AM–10:30 AM
10:30 AM–11:30 AM
SY40
SYMPOSIUM
Predictive Biomarkers in Melanoma
Festsaal
Chairs:
J. Becker (Essen, Germany)
C. Krepler (Philadelphia, USA)
10:30 AM–10:50 AM
SY40-1
What should an ideal biomarker look like?
J. Becker (Essen, Germany)
10:50 AM–11:10 AM
SY40-2
Biomarkers for targeted therapies
beyond B-raf status
D. Schadendorf (Essen, Germany)
11:10 AM–11:30 AM
SY40-3
Preclinical evaluation of biomarkers
to predict therapeutic response
C. Krepler (Philadelphia, USA)
10:30 AM–11:30 AM
SY41
SYMPOSIUM
New Methods in Early Detection of Skin Cancer
G. Pellacani (Modena, Italy)
P. Soyer (Brisbane, Australia)
10:30 AM–10:45 AM
SY41-1
Confocal microscopy/multiphoton imaging
G. Pellacani (Modena, Italy)
10:45 AM–11:00 AM
SY41-2
Electric impedance spectroscopy
J. Malvehy (Barcelona, Spain)
11:00 AM–11:15 AM
SY41-3
Total body photography
A. Halpern (New York, USA)
11:15 AM–11:30 AM
SY41-4
“Apps” and telemedicine
H. P. Soyer (Brisbane, Australia)
SAT
Chairs:
INDEX
Zermoniensaal
POSTER
FRI
Rituximab monotherapy for primary cutaneous
B-cell lymphoma: response and long-term followup in 24 patients
C. Jonak (Vienna, Austria)
COFFEE BREAK
THU
WED
SCIENTIFIC PROGRAM
09:48 AM–10:00 AM
Saturday, September 3, 2016
52
Scientific Program
SY42
SYMPOSIUM
M. Preusser (Vienna, Austria)
A. Berghoff (Vienna, Austria)
10:30 AM–10:45 AM
SY42-1
Biology of brain metastases
A. Berghoff (Vienna, Austria)
10:45 AM–11:00 AM
SY42-2
The leptomeningeal microenvironment
as protective sanctuary for melanoma cells
I. Fedorenko (Tampa, USA)
11:00 AM–11:15 AM
SY42-3
How do the new therapies influence
our algorithms for brain metastases?
M. Preusser (Vienna, Austria)
11:15 AM–11:30 AM
SY42-4
Surgery for brain metastases
from cutaneous tumors
J.-C. Tonn (Munich, Germany)
11:35 AM–12:05 PM
PL5
PLENARY LECTURE
The future of dermatooncology
C. Garbe (Tuebingen, Germany)
OT4
CLOSING CEREMONY
FRI
PL5-1
SAT
H. Pehamberger (Vienna, Austria)
C. Hoeller (Vienna, Austria)
C. Hoeller (Vienna, Austria)
INDEX
Festsaal
Chairs:
THU
Future Targets and Combinations
Festsaal
12:05 PM–12:30 PM
WED
Chairs:
SCIENTIFIC PROGRAM
Brain Metastases
Rittersaal
POSTER
10:30 AM–11:30 AM
Saturday, September 3, 2016
53
POSTER
INDEX
SAT
FRI
THU
WED
SCIENTIFIC PROGRAM
Scientific Program
A
Agarwala, Sanjiv SY29; SY36,
SAT7; Chair SY36
Alcalay, Joseph SY9
Andtbacka, Robert HI SY18; SY31;
SY36; Chair SY31
Arenberger, Peter SY1; Chair SY16
Argenziano, Giuseppe SY3
Ascierto, Paolo SY26; SY32;
Chair SY26
B
Bagot, Martine SY23
Barnhill, Raymond L SY14
Bastian, Boris PL2; SY19; SY24;
Chair SY24
Becker, Juergen SY33; SY40; SAT1;
Chair SY40, SAT1
Beissert, Stefan SY30
Berghoff, Anna SY42; Chair SY42
Binder, Michael SY29; Chair SY29
Blank, Christian PL3; SY26; SY32,
SAT7; Chair SY26
Braathen, Lasse SY17
Busam, Klaus J. SY14
Bylaitė-Bučinskienė,
Mathilda Chair SY27
C
Clark, Rachel SY23; PL4
D
Dreno, Brigitte SY12; FC3;
Chair SY12
Dummer, Reinhard SY10, SY12;
SY32; SY36, SAT5; Chair SY16
Duvic, Madeleine SY23;
54
List of Chairs and Invited Speakers
F
Fargnoli, Maria Concetta SY4;
Chair SY4
Fedorenko, Inna SY42
Forsea, Anna Maria SY6; Chair SY6
Funovics, Philipp SY33
G
Garbe, Claus SY15; SY34; PL5,
SAT3; Chair PL2, SAT3
Geller, Allen SY1, SY35
Gershenwald, Jeff SY9; SY15;
SY31; Chair SY34
Geskin, Larissa SY20; Chair SY23
Geusau, Alexandra SY35;
Chair SY35
Gnant, Michael SY15; Chair SY15
Gogas, Helen SY22; Chair SY22
Grabbe, Stephan SY7; Chair SY7
Grob, Jean-Jaque SY8; SY22; SAT2;
SAT3; Chair SY8, SAT2
Gutzmer, Ralf SY20; SY27; SAT2;
Chair SY20
H
Haass, Nikolas SY11; Chair SY32
Hahn, Heidi SY10; Chair SY10
Halpern, Allan SY1; SY41;
Chair PL2
Handisurya, Alessandra SY13;
Chair SY13
Hauschild, Axel SY8; SY32; SAT7;
Chair SY8, SAT7
Hayward, Nick SY24; SY2;
Chair SY2; FC1
Herlyn, Meenhard SY2; Chair
SY2, FC1
Hoeller, Christoph SY6; SAT4;
SAT6; Chair PL1, PL5, SY19, SAT6,
FC3, OT4
Hofbauer, Guenther SY13; SY27;
Chair SY13
Hofmann-Wellenhof, Rainer SY3
Hoenigsmann, Herbert SY30;
Chair SY30
J
Janda, Monika SY1
K
Kandolf-Sekulovic,
Lidia Chair SY36
Kaufmann, Roland SY9; Chair SY9
Kirkwood, John SY22; SY29;
Chair PL4
Kirnbauer, Reinhard SY2
Kittler, Harald SY3; SY19; SY25;
Chair SY3
Knobler, Robert SY23; Chair PL4
Krepler, Clemens SY40; Chair SY40
Kumar, Rajiv SY24
Kunstfeld, Rainer SY13; SY27;
Chair SY10
Kupper, Thomas SY7
L
Larkin, James SY16; PL4; SAT2,
SAT5, SAT6; Chair SAT5
Lebbé, Céleste SY35; SY38; SAT1;
SAT6; Chair SY21
Lehner-Baumgartner, Eva SY37;
Chair SY37
Lichtenberger Beate SY2;
Chair SY2
Lim, Henry SY30; Chair SY30
P
Papadavid, Evangelia Chair SY23
Paulitschke, Verena SY11;
Chair SY11
Pehamberger, Hubert Chair PL1,
SY22, SY29, SY34, PL5, SAT4,
FC2
Pellacani, Giovanni SY41;
Chair SY41
Petzelbauer, Peter FC1;
Chair SY14, FC1
Posch, Christian FC3; Chair FC3
SCIENTIFIC PROGRAM
WED
S
Sahin, Ugur PL2; SY18; Chair SY18
Saiag, Philippe SY33; Chair SY33
Sarnoff, Deborah SY30
Scarisbrick, Julia SY5; Chair SY5
Schadendorf, Dirk SY8, SY12;
SY40; Chair PL3
Schindler, Katja SY21; SY38;
Chair SY38
Schramek, Daniel SY11;
Chair SY11
Schuetzl, Philipp SY37
Schuler, Gerold SY18; Chair SY18
Schwarz, Thomas SY2
Schwenzer, Nina SY39;
Chair SY39
Sekulic, Aleksandar PL1; SY10
Sibaud, Vincent SY21; Chair SY21
Smalley, Keiran SY26; Chair SY32
Sober, Arthur Joel SY14
Sotiriou, Eleni SY17
Soyer, H. Peter SY41; Chair SY41
T
Testori, Alessandro SY22; SY31;
Chair SY15
Thomas, Luc SY25
Tonn, Joerg-Christian SY42
Trautinger, Franz SY23
Tschachler, Erwin SY2
Tschandl, Philipp SY25;
Chair SY19
Tueting, Thomas SY28; Chair SY28
THU
R
Radakovic, Sonja SY17; Chair SY17
Robins, Perry Chair SY1
Roesch, Alexander SY 26
Roka, Florian SY9; Chair SY9
Rosendahl, Cliff SY25; Chair SY25
Ross, Merick SY15; SY31; SY34;
Chair SY31
FRI
O
Okamoto, Ichiro SY4; Chair SY24
Olah, Judith Chair SY35
Q
Qualigno, Petro Chair SY5
Stadler, Rudolf SY23
Steiner, Andreas Chair FC2
Stengel, Fernando SY1
Stingl, Georg SY28; Chair SY28
Stockfleth, Eggert SY13; FC2
Stolz, Wilhelm SY25; Chair SY25
Stratigos, Alexander SY10; SY27;
Chair SY27
Szeimies, Rolf-Markus SY17;
Chair SY17
V
Vermeer, Maarten SY5
W
Wadsak Wolfgang SY39
Weber, Jefrey PL1; SY12; SAT6,
SAT7; Chair SY12
Weninger, Wolfgang SY7; SY28;
Chair SY7
Willemze, Rein SY5
Whittaker, Sean SY5
Wolff, Klaus Chair PL1
Z
Zalaudek, Iris SY3; SAT3; Chair SY3
Zielinski, Christoph SY29
55
SAT
M
Malvehy, Josep SY3; SY41;
Chair SY4
Markel, Gal SY28
Marmol, Veronique Del SY1;
Chair SY1
Mayerhoefer, Marius SY39;
Chair SY39
McArthur, Grant SY4; SY8; SY24;
Chair PL3
Michielin, Olivier SY16; PL3; SAT4
Mihm, Martin C SY14; Chair SY14
Mitterhauser, Markus SY39
Mohr, Peter SY6; Chair SY6
Mueller, Markus FC2
Preusser, Matthias SY42;
Chair SY42
Puig, Susanna SY3; SY25
INDEX
Loewe, Robert SY20; SY33;
Chair SY33
Loquai, Carmen SY38; Chair SY38
Lorigan, Paul SY20; Chair SY20
List of Chairs and Invited Speakers
POSTER
Scientific Program
Scientific Program
Poster Exhibition
SCIENTIFIC PROGRAM
Please see the scientific program on p. 32 and p. 50 for the thematic distribution
of the posterwalks..
P001 Cobimetinib plus vemurafenib for unresectable or metastatic melanoma: characteristics
and safety data in 376 patients from the French temporary authorization for use
Dreno B.1, Zehou O.2, Meyer N.3, Mateus C.4, Duval Modeste A.‑B.5, Lebbe C.6
1
CHU de Nantes – Hotel Dieu, Department of Dermatology, Nantes, France, 2Hôpital Henri Mondor, Department
of Dermatology, Créteil, France, 3IUCT – Oncopole, Department of Dermatology, Toulouse, France, 4Gustave Roussy,
Department of Dermatology, Villejuif, France, 5CHU de Rouen – Hôpital Charles Nicolle, Department of Dermatology,
Rouen, France, 6Hôpital Saint-Louis, Department of Oncology, Paris, France
P002 Malignant melanoma in Ukraine: Figures and features
Korovin S.1, Kukushkina M.1, Goulak L.2, Fedorenko Z.2, Palivets A.1, Ostafiichuk V.1, Kovalchuk P.3
National Cancer Institute, Department of Skin and Soft Tissue Tumors, Kiev, Ukraine, 2National Cancer Institute,
Department of Cancer Epidemiology, Kiev, Ukraine, 3National Cancer Institute, Oncologic Orthopedy, Kiev, Ukraine
1
P003 Eleven years of melanoma patient management – observations and trends from a single‑center
experience in Austria
Posch C.1, Feichtenschlager V.1, Weihsengruber F.1, Rappersberger K.1
The Rudolfstiftung Hospital, Dermatology, Vienna, Austria
P004 Retrospective analysis of clinical and histopathologic characteristics of Malignant Melanoma:
an analysis of 24 years’ data from the Department of Dermatology in Cracow, Poland
Wawrzynkiewicz M.1, Podolec K.1, Szworak M.1, Wojas‑Pelc A.1
Jagiellonian University, Collegium Medicum, Department of Dermatology, Cracow, Poland
POSTER
INDEX
SAT
FRI
THU
1
P005 Ranking of risk factors for cutaneous malignant melanoma in the general population:
A systematic review and meta-analysis
Joosten V.H.M.J.1, Kelleners‑Smeets N.W.J.1, Dinant G.J.2, Smeets J.G.E.2, Steijlen P.M.1, Nelemans P.J.3
1
GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands, 2CAPHRI
School for Public Health and Primary Care, Family medicine, Maastricht, Netherlands, 3CAPHRI School for Public Health
and Primary Care, Epidemiology, Maastricht, Netherlands
P006 Influence of socioeconomic status on clinical outcomes of malignant melanoma:
a cross-sectional study in 746 patients
Molgó M.1, Andino R.1, Navajas L.1, Silva M.J.2, Uribe P.1, Sazunic I.3, González S.2
Pontificia Universidad Católica de Chile, Dermatology, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago,
Chile, 3Universidad
de Chile, Santiago, Chile
1
P007 Clinicopathological characteristics, treatment patterns and outcome of cutaneous melanoma
in South‑East Europe: first results from the national registry of Serbian Melanoma Group
Kandolf Sekulovic L.1, Babovic N.2, Nikolin B.3, Vrbic S.4, Vukanovic T.1,
Ostojic N.5, Mijuskovic Z.1, Dinic M.1, Juskic K.2, Jevric M.2, Neric D.2, Todorovic M.4, Tiodorovic D.4,
Nikolic D.6, Novakovic M.5, Serbian Melanoma Group
1
Medical Faculty, Military Medical Academy, Dermatology and Venerology, Belgrade, Serbia, 2Institute of Oncology and
Radiology of Serbia, Melanoma and Sarcoma unit, Belgrade, Serbia, 3Institute of oncology of Vojvodina, Melanoma Unit,
Novi Sad, Serbia, 4Clinical Center of Nis, Medical Oncology, Nis, Serbia, 5Medical Faculty, Military Medical Academy, Plastic
and Reconstructive Surgery, Belgrade, Serbia, 6Clinical Hospital Center ‘Bezanijska Kosa’, Surgical oncology, Belgrade,
Serbia
56
MELANOMA
WED
1
Scientific Program
Poster Exhibition
P008 A single-center study on 118 re-excisions and 136 sentinel node biopsies for malignant
melanoma
Asdahl K.R.1, Stolle L.B.2
MELANOMA
P009 Tumor necrosis factor alpha production is icreased in vitro bearing the R151C variant of MC1R gene
Córdoba‑Lanús E.1, Espinoza‑Jiménez A.1, Ramos‑Trujillo E.1, Almeida‑González D.2,
Fernández‑de‑Misa R.1,3
Hospital Universitario Nstra. Sra. de Candelaria, Research Unit, Santa Cruz de Tenerife, Spain, 2Hospital Universitario
Nstra. Sra. de Candelaria, Immunology Department, Santa Cruz de Tenerife, Spain, 3Hospital Universitario Nstra. Sra. de
Candelaria, Dermatology Department, Santa Cruz de Tenerife, Spain
1
P010 The HDL receptor controls the metabolic phenotype of human metastatic melanoma cells
Kinslechner K.1, Schörghofer D.1, Schütz B.1, Vallianou M.1, Röhrl C.2, Hengstschläger M.1, Moriggl R.3,
Stangl H.2, Mikula M.1
SCIENTIFIC PROGRAM
1
Regionshospitalet Randers, Department of Abdominal Surgery, Randers, Denmark, 2Sygehus Lillebelt, Vejle,
Department of Plastic Surgery, Vejle, Denmark
Medical University of Vienna, Institute of Medical Genetics, Vienna, Austria, 2Medical University of Vienna, Institute
of Medical Chemistry, Vienna, Austria, 3University of Veterinary Medicine and Medical University Vienna, Ludwig
Boltzmann Institute for Cancer Research, Vienna, Austria
Fundiert
Wissenschaftlichen Beiträge aus internationalen
Fachpublikationen in deutscher Übersetzung
Kompetent
Auswahl und praxisrelevante Kommentierung
von Peer-Review-Arbeiten durch namhaften
Fachbeirat
Praxisnah
Übersichtlich aufbereitete Informationen für
Fachärzte für Haut- & Geschlechtskrankheiten
Neugierig?
Bestellen Sie gleich
hier ein kostenloses
Probeheft:
S. Karger
Medical and Scientific Publishers
Basel . Freiburg . Paris . London .
New York . Chennai . New Delhi .
Bangkok . Beijing . Shanghai .
Tokyo . Kuala Lumpur .
Singapore . Sydney
Wissenstransfer aus
Unseren Abo-Service
erreichen Sie unter:
t +49 761 45 207-24, f -14
[email protected]
Besuchen Sie unsere
Homepage:
57
www.karger.com/kkd
THU
FRI
Wissenstransfer aus der
Forschung in die Praxis
SAT
Medical University of Vienna, Pharmacology, Vienna, Austria
1
INDEX
Pharmacological targeting of the IL-6 signalling pathway in human melanoma cells
of different stages
Wasinger C.1, Svoboda K.1, Hohenegger M.1
POSTER
P011
WED
1
Scientific Program
Poster Exhibition
P012 Diverse gene expression changes under targeted inhibitor treatment of primary melanoma cell
cultures
Cheng P.1, Freiberger S.1, Dummer R.1, Levesque M.1
University Hospital Zurich, Dermatology, Zurich, Switzerland
SCIENTIFIC PROGRAM
1
P013 Choline transporter-like proteins as a novel molecular target for the therapy of melanoma
Inazu M.1,2, Yamanaka T.2
Tokyo Medical University, Institute of Medical Science, Tokyo, Japan, 2Tokyo Medical University, Department of Molecular
Preventive Medicine, Tokyo, Japan
1
P014 CXCL5 alters metastatic patterns of malignant melanoma
Forsthuber A.1, Lipp K.1, Gröger M.2, Loewe R.1,3
Medical University of Vienna, Skin & Endothelium Research Division SERD, Department of Dermatology, Vienna, Austria,
Medical University of Vienna, Core Facility Imaging, Vienna, Austria, 3Medical University of Vienna, Division of General
Dermatology and Dermatooncology, Department of Dermatology, Vienna, Austria
1
2
P016 RRE inhibit melanogenesis in B16F0 melanoma cells through MAP kinase pathway
Chien T.‑Y.1, Wang H.‑W.1, Liao H.‑F.1, Lin I.‑H.1, Lo Y.‑F.1, Chiang H.‑M.1, Wen K.‑C.1, Takashi Y.2
China Medical University, Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University Corporation Kitami
Institute of Technology, Hokkaido, Japan
1
FRI
1
University of Sydney, Discipline of Anatomy and Histology, Bosch Institute, School of Medical Sciences, Sydney Medical
School, Sydney, Australia, 2Discipline of Physiology, Bosch Institute, University of Sydney, School of Medical Sciences,
Sydney Medical School, Sydney, Australia
P018 Cost-effectiveness of population-based skin cancer screening
Hoorens I.1, Pil L.2, Vossaert K.3, Annemans L.2, Brochez L.1
POSTER
INDEX
SAT
P017 PTEN: a novel target for vitamin D in the fight against melanoma
Shariev A.1, Painter N.1, Mason R.2, Dixon K.1
University Hospital Ghent, Dermatology, Ghent, Belgium, 2University Hospital Ghent, Public Health, Ghent, Belgium,
Private Practice, Maldegem, Dermatology, Maldegem, Belgium
1
3
P019 Effect and mechanisms of MGE in melanoma cells
Liu Y.‑J.1, Wang H.‑W.1, Chen P.‑W.1, Lu X.‑Y.1, Hsu L.‑Y.1, Takashi Y.2, Wen K.‑C.1, Chiang H.‑M.1
1
China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2National University
Corporation Kitami Institute of Technology, Hokkaido, Japan
P020 Primary cutaneous malignant melanoma: not a rarity in Asian skin
Saikia U.N.1, Khullar G.2, De D.2, Handa S.2, Radotra B.D.1
Post Graduate Institute of Medical Education and Research, Histopathology, Chandigarh, India, 2Post Graduate Institute
of Medical Education and Research, Dermatology, Chandigarh, India
1
58
MELANOMA
1
Sydney Melanoma Diagnostic Centre, Dermatology, Sydney, Australia, 2São Paulo University, Dermatology
Department of Hospital das Clínicas, São Paulo, Brazil, 3Melanoma Institute Australia, Dermatology, Sydney,
Australia, 4Melanoma Institute Australia, Statistics, Sydney, Australia
THU
WED
P015 Analysis of an electrical impedance spectroscopy system in short-term digital dermoscopy
imaging of melanocytic lesions
Rocha L.1,2, Guitera P.1,3, Khoury R.1, Avramidis M.3, Lo S.4, Menzies S.1
Scientific Program
Poster Exhibition
P021 Evaluation of nodal cellular morphology and pigmentation as prognostic factors in melanoma
patients with positive sentinel nodes
Bertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.1
P022 Micromorphometric evaluation of sentinel nodes in melanoma patients: The value of metastatic
size, localization, and depth
Bertolli E.1, Macedo M.P.2, Molina A.S.1, Damascena A.S.3, Pinto C.A.L.2, Duprat Neto J.P.1
1
AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo,
Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil
P023 A retrospective study of the pathological prognostic indicators of small diameter melanoma
Coltart H.1, Dawar B.1, Darling M.2, Moyes C.3, Gupta G.4
1
University of Glasgow, Glasgow, United Kingdom, 2Queen Elizabeth University Hospital, Dermatology, Glasgow, United
Kingdom, 3Queen Elizabeth University Hospital, Pathology, Glasgow, United Kingdom, 4NHS Lanarkshire, Dermatology,
Glasgow, United Kingdom
SCIENTIFIC PROGRAM
1
AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São Paulo,
Brazil, 3AC Camargo Cancer Center, International Center for Research, São Paulo, Brazil
P024 Spitz tumors and other histopathological pitfalls: Diagnosis with Dermato fluoroscopy
Giering H.‑G.1, Buder S.2, Stankovic G.1, Leupold D.1
Magnosco GmbH, Berlin, Germany, 2Vivantes-Klinikum Berlin Region Süd, Berlin, Germany
WED
P025 Histological features of metastatic melanoma under targeted therapies - A report of 3 cases
Goldman-Lévy G.1,3, Laurent-Bellue A.1, Plantier F.1, Just P.-A.1,3, Rouquette A.1, Beuvon F.1, Dallot A.1,
Aractingi S.2,3, Carlotti A.1, Kramkimel N.2, Avril M.-F.2,3, Terris B.1,3
THU
1
Hôpital Cochin, Dept. of Pathology, Paris, France, 2Hôpital Cochin, Dept. of Dermatology, APHP Groupe Hospitalier Paris
Centre, Paris, France, 3Université Paris Descartes, Faculty of Medecine Paris Descartes, Paris, France
FRI
P026 New in complex non-invasive diagnosis of melanoma
Kurdina M.1, Makarenko L.2, Lebedeva A.3, Kurdina E.1
GK ‘MEDSI’, Dermatology, Moscow, Russian Federation, 2Research Center of Russian Railways, Dermatology, Moscow,
Russian Federation, 3International Medical Leech Centre, Dermatology, Udelnaya pos, Russian Federation
1
SAT
P028 Two-photon-excitation melanin fluorescence measurement for melanoma detection
Nouri N.1, Spänkuch I.1, Lomberg D.1, Tampouri I.1, Forschner A.1, Garbe C.1
Eberhard Karl University, University Department of Oncology, Tübingen, Germany
INDEX
1
P029 Pre-operative imaging for newly diagnosed primary melanoma: Stage 0 – stage IIC
Callaghan D.1, Kakar R.2, Jang S.3, Venna S.3
1
Boston University, Dermatology, Boston, United States, 2University of Oklahoma, Dermatology, Oklahoma City, United
States, 3Inova Schar Cancer Institute, Fairfax, United States
POSTER
MELANOMA
1
P030 Melapred: first susceptibility test to sporadic melanoma in daily dermatological practice
Soufir N.1,2, Benfodda M.1,2, Gazal S.3, Descamps V.4, Madjlessi N.5, Lebbe C.6, Basset‑Seguin N.6,
Archimbaud A.6, Opletalova K.4, Vuong V.4, Nicaise‑Bergere C.7, Massart‑Manil S.7, Machuel B.8,
Saiag P.9, Merrouche Y.10, Bensussan A.2, Nagore E.11, Kumar R.12, Grange F.13
1
Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital, Biostatistic,
Paris, France, 4Bichat Hospital, Dermatology, Paris, France, 5Private Practice, Dermatology, Paris, France, 6Saint Louis
Hospital, Dermatology, Paris, France, 7Private General Practice, Reims, France, 8Private General Practice, Rilly La
Montagne, France, 9Ambroise Pare Hospital, Dermatology, Boulogne Billancourt, France, 10Jean Godinot Institute, Reims,
France, 11Instituto di Oncologia, Dermatology, Valencia, Spain, 12German Cancer Research Center, Division of Molecular
Genetic Epidemiology, Heidelberg, Germany, 13CHU de Reims, Dermatology, Reims, France
59
Scientific Program
Poster Exhibition
SCIENTIFIC PROGRAM
P031 MELADIAG: a panel of DNA biomarkers dedicated to melanoma diagnosis
Benfodda M.1,2, Marinho E.3, Kumar R.4, Lamoril J.1, Beaudoux O.5, Reocreux M.1, Grange F.6,
Dechamps L.3, Bensussan A.2, Merrouche Y.7, Soufir N.1,2
1
Bichat Hospital, Genetic, Paris, France, 2Centre de recherche sur la peau, U976, Paris, France, 3Bichat Hospital,
Pathological Anatomy, Paris, France, 4German Cancer Research Center, Division of Molecular Genetic Epidemiology,
Heidelberg, Germany, 5Jean Godinot Institute, Dermatology, Reims, France, 6CHU de Reims, Dermatology, Reims, France,
7
Jean Godinot Institute, Reims, France
P032 Epidemiological pattern of patients with melanoma in Minsk region (Belarus) using digital
dermoscopy (2013–2014)
Prakoshyn A.1, Zhukavets A.2, Lud N.3
Vitebsk Regional Oncology Center, Vitebsk State Medical University, General Oncology, Vitebsk, Belarus, 2N.N.
Alexandrov National Cancer Centre of Belarus, Minsk Region, Belarus, 3Vitebsk State Medical University, Vitebsk, Belarus
1
P033 Spectrophotometric method of intradermal test for pigmented skin lesions diagnosis
Sokolova A.1, Malishevskaya N.2
Ural Medical Clinic, Yekaterinburg, Russian Federation, 2Ural Research Institute of Dermatology,
Venerology and Immunopathology, Yekaterinburg, Russian Federation
1
P034 The deceiving faces of melanoma
Rados J.1, Loncaric D.1, Bradamante M.1, Ilic I.2, Marinovic B.1
UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia,
UHC Zagreb and School of Medicine, University of Zagreb, Department of Pathology, Zagreb, Croatia
2
P035 Mobile teledermoscopy. A useful tool to evaluate suspicious lesions. Pilot project in Rosario,
Argentina
Alonso C.1, Salerni G.1, Fernandez Bussy R.1
Hospital Provincial del Centenario, Dermatology, Rosario, Argentina
P036 Dermoscopic features of scalp melanoma
Oganesian M.1, Smirnova I.1, Dobrovolskiy E.2, Getman A.3
1
Saint-Petersburg State University, Medical Faculty, Department of Infectious Diseases, Epidemiology and
Dermatovenereology, Saint-Petersburg, Russian Federation, 2Svedlovsk Regional Dermatovenerologic Dispensary,
Branch No.2, Nizhny Tagil, Russian Federation, 3Medical Center ‘Neo Clinic’, Department of Oncology, Tyumen, Russian
Federation
POSTER
INDEX
SAT
FRI
1
P037 Decreasing dermoscopy score of pigmented lesions following treatment with mild
immunostimulatory treatment
Russu L.1, Sprincenatu C.1, Russu M.2, Russu E.3
1
Bioderm Medical Center, Bucharest, Romania, 2Bio Medica, Bucharest, Romania, 3Bioderm Laser Clinic, Bucharest,
Romania
P038 Future of care for patients at high risk for melanoma: from multimode, hyperspectral
dermoscopy to self‑imaging with smartphone
Farkas D.L.1,2, Vasefi F.1, MacKinnon N.B.1, Durkin A.J.3, Kelly K.M.3
Spectral Molecular Imaging Inc., Beverly Hills, United States, 2University of Southern California, Los Angeles, United
States, 3University of California, Irvine, United States
1
P039 Small diameter melanomas – two case reports
Štulhofer Buzina D.1, Čeović R.1, Bradamante M.1, Lončarić D.1, Jurakić Tončić R.1
1
University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology
and Venereology, Zagreb, Croatia
60
MELANOMA
THU
WED
1
Scientific Program
Poster Exhibition
P040 Sudden eruption of multiple Meyerson naevi
Jerkovic Gulin S.1, Rados J.2, Loncaric D.2, Ceovic R.2,3, Marinovic B.2,3
SCIENTIFIC PROGRAM
1
General Hospital Sibenik, Infectious Diseases and Dermatology and Venereology, Sibenik, Croatia, 2University Hospital
Center Zagreb, Department of Dermatology and Venereology, Zagreb, Croatia, 3University of Zagreb School of Medicine,
Zagreb, Croatia
P041 Total number of common and atypical melanocytic nevi in patients with melanoma in Turkey
Sallahoglu K.1, Cengiz F.P.1, Emiroglu N.1, Erdogan Güven Z.2, Onsun N.1
Bezmialem Vakif University, Istanbul, Turkey, 2University of Kragujevac, Kragujevac, Serbia
1
P042 Nevus lipomatosus cutaneus superficialis of the scalp in association with melanocytic nevus
Tsekova Traykovich N.1, Grozdev I.1, Balabanova M.1, Miteva L.1
Medical University Sofia, Dermatology and venereology, Sofia, Bulgaria
1
P043 Characteristics of Lymphangiogenesis in Melanoma
Wenzina J.1, Puujalka E.1, Petzelbauer P.1
Medical University of Vienna, Skin & Endothelium Research Division (SERD), Vienna, Austria
1
THU
P045 Single-center “real life experience” with pembrolizumab (PEMBRO) in advanced melanoma
patients and analysis of baseline factors that correlate with outcome
Jansen Y.1, Schreuer M.1, Neyns B.1
WED
1
Medical University of Vienna, Medical Genetics, Vienna, Austria, 2IMC University of Applied Sciences Krems, Department
Life Sciences, Krems, Austria, 3Sciotec Diagnostic Technologies GmbH, Tulln, Austria, 4FIANOSTICS GmbH, Wr. Neustadt,
Austria
UZ Brussel, Oncologie, Jette, Belgium
1
FRI
P046 Expression of MAGL as a tumor progression marker in malignant melanoma
Baba Y.1, Tanese K.1, Mori M.1, Funakoshi T.1, Amagai M.1
Keio University School of Medicine, Department of Dermatology, Shinjuku, Japan
1
SAT
P047 Genetic polymorphisms in toll like receptors genes as prognostic biomarkers in melanoma
patients
Supic G.1, Ostojic N.2, Kandolf Sekulovic L.3, Vukanovic T.3, Rajovic M.2, Mijuskovic Z.3, Magic Z.1
INDEX
1
Medical Faculty, Military Medical Academy, Institute for Medical Research, Belgrade, Serbia, 2Medical Faculty, Military
Medical Academy, Plastic and Reconstructive Surgery, Belgrade, Serbia, 3Medical Faculty, Military Medical Academy,
Dermatology and Venerology, Belgrade, Serbia
POSTER
MELANOMA
P044 Generation of an affinity purified antibody for the detection of metastatic melanoma
Schütz B.1, Koppensteiner A.2, Hundsberger H.2, Missbichler A.3,4, Mikula M.1
P048 Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib combined with
vemurafenib in BRAFV600-mutant melanoma
Daud A.1, Pavlick A.C.2, Ribas A.3, Gonzalez R.4, Lewis K.D.4, Hamid O.5, Gajewski T.F.6, Puzanov I.7,
Hsu J.J.8, Rooney I.8, Choong N.W.8, Mcarthur G.A.9,10
1
University of California, San Francisco School of Medicine, Medicine (Hematology/Oncology), San Francisco, United
States, 2New York University Medical Center, New York, United States, 3Jonsson Comprehensive Cancer Center, University
of California, Los Angeles, Los Angles, United States, 4University of Colorado Comprehensive Cancer Center, Aurora,
United States, 5The Angeles Clinic and Research Institute, Los Angeles, United States, 6The University of Chicago, Chicago,
United States, 7Vanderbilt-Ingram Cancer Center, Nashville, United States, 8Genentech, Inc., South San Francisco, United
States, 9Peter MacCallum Cancer Centre, East Melbourne, Australia, 10University of Melbourne, Parkville, Australia
61
Scientific Program
Poster Exhibition
SCIENTIFIC PROGRAM
P049 Timing of onset and resolution of adverse events in patients with unresectable stage IIIB–IVM1a
melanoma treated with talimogene laherparepvec (T-VEC) in OPTiM
Andtbacka R.1, Kaufman H.2, Harrington K.3, Middleton M.4, Melcher A.3, Ottensmeier C.5, Safaei R.6,
Downey G.7, He P.8, Collichio F.9
1
Huntsman Cancer Institute, University of Utah, Salt Lake City, United States, 2Rutgers Cancer Institute of New Jersey,
New Brunswick, United States, 3The Institute of Cancer Research/The Royal Marsden Hospital NIHR Biomedical Research
Centre, London, United Kingdom, 4Oxford NIHR Biomedical Research Centre, Department of Oncology, Oxford, United
Kingdom, 5University of Southampton and University Hospital Southampton NHS Foundation Trust, Cancer Sciences Unit,
Southampton, United Kingdom, 6Amgen (Europe) GmBH, Zug, Switzerland, 7Amgen Ltd., Cambridge, United Kingdom,
8
Amgen Inc., Thousand Oaks, United States, 9The University of North Carolina, Chapel Hill, United States
P050 Impact of endoplasmic reticulum stress on melanoma malignancy
Eigner K.1, Filik Y.1, Klambauer G.2, Swoboda A.3, Moriggl R.3, Stangl H.1, Mikula M.1, Röhrl C.1
1
Medical University of Vienna, Vienna, Austria, 2Johannes Kepler University, Linz, Austria, 3Ludwig Boltzmann Institute
Cancer Research, Vienna, Austria
P051 The value of PET/CT patterns in response prediction of metastasized melanoma treated
with ipilimumab
Urosevic‑Maiwald M.1, Goldinger S.M.1, Sommerauer M.2, Dummer R.1, Schaefer N.G.2,3
P054 Electrochemotherapy in the treatment of metastatic malignant melanoma:
Results from the InspECT registry
Kunte C.1,2, Letule V.2, Gehl J.3, Dahlstroem K.4, Curatolo P.5, Rotunno R.5, Muir T.6, Occhini A.7,
Bertino G.7, Powell B.8, Saxinger W.9, Lechner G.9, Liew S.H.10, Pritchard Jones R.10, Rutkowski P.11,
Zdzienicki M.11, Mowatt D.12, Sykes A.J.13, Orlando A.14, Mitsala G.14, Rossi C.R.15,16, Campana L.15,16,
Brizio M.17, de Terlizzi F.18, Quaglino P.17, Odili J.8
Artemed Fachklinik, Department of Dermatologic Surgery and Dermatology, Munich, Germany, 2Ludwig-Maximilian
University Munich, Department of Dermatology and Allergology, Munich, Germany, 3Copenhagen University
Hospital Herlev, Center for Experimental Drug and Gene Electrotransfer, Department of Oncology, Herlev, Denmark,
4
Copenhagen University Hospital Herlev, Department of Plastic Surgery, Herlev, Denmark, 5University of Rome “La
Sapienza”, Department of Dermatology and Plastic Surgery, Rome, Italy, 6James Cook University Hospital, Department
of Reconstructive Plastic Surgery, Middlesbrough, United Kingdom, 7University of Pavia, Department of Otolaryngology
Head & Neck Surgery, Pavia, Italy, 8St. Georges Hospital, Department of Plastic Surgery, London, United Kingdom,
9
Klinikum Wels-Grieskirchen, Department of Dermatology, Wels, Austria, 10Whiston Hospital, Department of Plastic
Surgery, Prescot, United Kingdom, 11Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Department of Soft Tissue/Bone Sarcoma and Melanoma, Warsaw, Poland, 12Christie Hospital, NHS Foundation Trust,
Plastic Surgery Department, Manchester, United Kingdom, 13Christie Hospital, NHS Foundation Trust, Department of
Clinical Oncology, Manchester, United Kingdom, 14Southmead Hospital, North Bristol NHS Trust, Department of Plastic
and Reconstructive Surgery, Bristol, United Kingdom, 15University of Padova, Veneto Institute of Oncology IOV-IRCCS,
Padova, Italy, 16University of Padova, Department of Surgery Oncology and Gastroenterology, Padova, Italy, 17University
of Torino, Department of Medical Sciences, Dermatologic Clinic, Torino, Italy, 18IGEA, Scientific & Medical Department,
Carpi, Italy
POSTER
INDEX
SAT
FRI
1
P055 An exploratory study investigating the metabolic activity and local cytokine profile in melanoma
patients treated with pazopanib and paclitaxel
Thurneysen S.1, Cheng P.F.1, Nagel H.W.2, Kunz M.1, Jaberg‑Bentele N.1, Naegeli M.1,
Guenova‑Hötzenecker E.1, Goldinger S.1, Mangana J.1, Levesque M.P.1, Dummer R.1
University Hospital Zurich, Dermatology, Zuerich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zuerich,
Switzerland
1
62
MELANOMA
THU
WED
1
University Hospital Zurich, Dermatology, Zurich, Switzerland, 2University Hospital Zurich, Nuclear Medicine, Zurich,
Switzerland, 3Lausanne University Hospital, Nuclear Medicine and Molecular Imaging, Lausanne, Switzerland
Scientific Program
Poster Exhibition
P056 Sentinel lymph node biopsy for lower extremity melanoma with dual-basin uptake
on lymphoscintigraphy
Son J.1, Kim J.‑H.1, Hur N.1, Park I.1, Choe J.‑H.1, Kim J.S.1
P057 Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic
melanoma patients treated with vemurafenib in the BRIM-3 study
Hauschild A.1, Chapman P.B.2, Robert C.3, Larkin J.4, Haanen J.B.5, Ribas A.6, Hogg D.7, Hamid O.8,
Ascierto P.A.9, Testori A.10, Lorigan P.11, Dummer R.12, Sosman J.A.13, Flaherty K.T.14, Wongchenko M.J.15,
Yan Y.15, Chang I.15, Coleman S.15, Caro I.15, Mcarthur G.A.16,17
THU
WED
P058 TERT promoter mutations in patients with BRAFV600-mutated melanoma treated with
vemurafenib or cobimetinib combined with vemurafenib
Wongchenko M.J.1, Larkin J.2, Mcarthur G.A.3,4, Ribas A.5, Dréno B.6, Chapman P.B.7, Maio M.8,
Garbe C.9, Robert C.10, Lu W.1, Diala I.1, Darbonne W.C.1, Chang I.1, Hsu J.J.1, Caro I.1, Rooney I.1,
Ascierto P.A.11, Yan Y.1
Genentech, Inc., South San Francisco, United States, 2Royal Marsden NHS Foundation Trust, London, United Kingdom,
Peter MacCallum Cancer Centre, East Melbourne, Australia, 4University of Melbourne, Melbourne, Australia, 5Jonsson
Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, United States, 6Nantes University,
Nantes, France, 7Memorial Sloan Kettering Cancer Center, New York, United States, 8University Hospital of Siena, Siena,
Italy, 9University of Tuebingen, Tuebingen, Germany, 10Institut Gustave Roussy, Villejuif, France, 11Istituto Nazionale
Tumori Fondazione G. Pascale, Naples, Italy
1
FRI
3
SAT
P060 The Sentinel Lymph Node Biopsy in thin melanoma (Breslow ≤ 0.75mm and 0.76–1.0mm)
Kechagias G.1, Marra A.1, Karonidis A.1, Kyriopoulos E.1, Tsoutsos D.1
General Hospital ‘G. Gennimatas’, Plastic Surgery, Athens, Greece
INDEX
1
P061 Multi-center real-life experience with checkpoint inhibitors and targeted therapy agents in
advanced melanoma patients in Switzerland
Mangana J.1, Amann V.C.1, Goldinger S.M.1, Kaufmann C.2, Frauchiger A.L.1, Cheng P.1, Stögner V.3,
Held U.4, Von Moos R.5, Romano E.6, Michielin O.7, Braun R.1, Levesque M.P.1, Dummer R.1
POSTER
MELANOMA
1
University Hospital Schleswig-Holstein, Kiel, Germany, 2Memorial Sloan Kettering Cancer Center, New York, United
States, 3Institut Gustave Roussy, Paris, France, 4Royal Marsden NHS Foundation Trust, London, United Kingdom,
5
The Netherlands Cancer Institute, Amsterdam, Netherlands, 6Jonsson Comprehensive Cancer Center, University of
California, Los Angeles, Los Angeles, United States, 7Princess Margaret Hospital and University Health Network, Toronto,
Canada, 8The Angeles Clinic and Research Institute, Los Angeles, United States, 9Istituto Nazionale Tumori Fondazione
G. Pascale, Naples, Italy, 10Istituto Europeo di Oncologia, Milan, Italy, 11University of Manchester, Manchester, United
Kingdom, 12University of Zurich, Zurich, Switzerland, 13Vanderbilt University School of Medicine, Nashville, United States,
14
Massachusetts General Hospital, Boston, United States, 15Genentech, Inc., South San Francisco, United States, 16Peter
MacCallum Cancer Centre, East Melbourne, Australia, 17University of Melbourne, Parkville, Australia
SCIENTIFIC PROGRAM
1
Samsung Medical Center,Sungkyunkwan University School of Medicine, Department of Surgery, Seoul, Korea, Republic
of
University Hospital Zurich, Department of Dermatology, Zurich, Switzerland, 2University of Zurich, Zurich, Switzerland,
Medical University of Vienna, Vienna, Austria, 4Horten Centre for Patient Oriented Research and Knowledge Transfer,
Zurich, Switzerland, 5Cantonal Hospital Graubünden, Chur, Switzerland, 6Department of Oncology, Service of Medical
Oncology, Research Unit 932, Institut Curie, Paris, France, 7University of Lausanne and Centre Hospitalier Universitaire
Vaudois (CHUV), Department of Oncology, Lausanne, Switzerland
1
3
P062 Clinical and demographic characteristics of patients (pts) treated with vemurafenib
in real-world setting
Sadetsky N.1, Corvino F.2, Surinach A.2, Goodman G.1
Genentech, Inc., South San Francisco, United States, 2Genesis Research LLC, Hoboken, United States
1
63
Scientific Program
Poster Exhibition
SCIENTIFIC PROGRAM
P063 Trial in progress: Clinical trial of nivolumab combined with ipilimumab followed by nivolumab
monotherapy as first-line therapy of patients with stage III (unresectable) or stage IV melanoma:
CheckMate 401
Dummer R.1, Gutzmer R.2, Corrie P.3, Millward M.4, Murzhenko A.5, Maio M.6
1
UniversitätsSpital Zürich, Zurich, Switzerland, 2Medizinische Hochschule Hannover, Hannover, Germany, 3Addenbrooke’s
Hospital, Cambridge, United Kingdom, 4Sir Charles Gairdner Hospital, Nedlands, Australia, 5Bristol-Myers Squibb,
Princeton, United States, 6University Hospital of Siena, Siena, Italy
P064 Safety and anti-tumor activity of Pasireotide in patients with BRAF- and NRAS-wild type,
unresectable and or metastatic melanoma: A phase I, open-label, single-arm study
Schadendorf D.1, Michielin O.2,3, Nägeli M.4, Goldinger S.M.4, Campigotto F.5, Kriemler‑Krahn U.6,
Schmid H.A.6, Pedroncelli A.M.6, Micaletto S.4, Dummer R.4
University Hospital Essen, Department of Dermatology, Essen, Germany, 2Lausanne University Hospital (CHUV),
Multidisciplinary Oncology Center, Lausanne, Switzerland, 3Swiss Institute of Bioinformatics (SIB), Lausanne,
Switzerland, 4University Hospital Zürich, Department of Dermatology, Zürich, Switzerland, 5Novartis Pharmaceuticals
Corporation, East Hanover, United States, 6Novartis Pharmaceuticals AG, Basel, Switzerland
1
P065 Photodynamic therapy of dermatological melanoma using transoethosomes drug delivery
system
Rady M.1, Afifi N.2, Gomaa I.3, Abdel Kader M.4
Faculty of Pharmacy and Biotechnology, German University in Cairo, Pharmaceutical Technology, Cairo, Egypt, 2Faculty
of Pharmacy and Biotechnology, German University in Cairo, and Faculty of Pharmacy – Cairo University, Pharmaceutical
Technology, Cairo, Egypt, 3Faculty of Pharmacy and Biotechnology, German University in Cairo, Biotechnology, Cairo,
Egypt, 4German University in Cairo, Cairo, Egypt
1
Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Endocrine Surgery, Seoul, Korea,
Republic of, 2Samsung Medical Center, Sungkyunkwan University School of Medicine, Department of Surgery, Seoul,
Korea, Republic of
SAT
P067 Novel insights into hyperthermia´s therapeutic effectiveness in treating malignant melanoma
Mantso T.1, Vasiliadis S.2, Lampri E.3, Anestopoulos I.2, Botaitis S.4, Goussetis G.5, Chlichlia K.2,
Pappa A.2, Panagiotidis M.1
Heriot Watt University, School of Life Sciences, Edinburgh, United Kingdom, 2Democritus University of Thrace,
Department of Molecular Biology & Genetics, Alexandroupolis, Greece, 3University of Ioannina, Department of Pathology,
Medical School, Ioannina, Greece, 4Democritus University of Thrace, Second Department of Surgery, Medical School,
Alexandroupolis, Greece, 5Heriot Watt University, School of Engineering & Physical Sciences, Edinburgh, United Kingdom
POSTER
INDEX
1
P068 Radiation therapy in melanoma patients with poor clinical characteristics – a collaborative
experience with 107 patients
Posch C.1, Steffal C.2, Haider A.1, Flechl B.2,3, Kann T.2, Weihsengruber F.1, Schratter‑Sehn A.U.2
1
The Rudolfstiftung Hospital, Dermatology, Vienna, Austria, 2Kaiser- Franz-Josef Hospital, Institute for Radio-oncology,
Vienna, Austria, 3Medaustron, Wr. Neustadt, Austria
P069 Immunotherapy with human iPS-cell derived myeloid cell lines producing Type I interferons
against metastatic melanoma
Miyashita A.1, Fukushima S.1, Nakahara S.1, Kubo Y.1, Tokuzumi A.1, Senju S.2, Nishimura Y.2, Jinnin M.1,
Ihn H.1
Kumamoto University, Dermatology and Plastic Surgery, Kumamoto, Japan,
Kumamoto University, Immunogenetics, Kumamoto, Japan
1
2
64
MELANOMA
P066 Complete lymph node dissection could not be beneficial in sentinel lymph node positive patients
Hur N.1, Kim J.1, Son J.2
FRI
THU
WED
1
Scientific Program
Poster Exhibition
P070 Treatment of primary skin melanoma with traditional medicine methods
Stroka Koka A.1, Stroka L.1
ALMS Medical Care, Tirana, Albania
P071 CONVERCE: Evaluation of cobimetinib and vemurafenib combination treatment in patients
with brain metastases from BRAFV600 mutated melanoma
Lesimple T.1, Campillo‑Gimenez B.1, Leccia M.T.2, Mahmoudi A.3, Lebbe C.4, French Dermatology Society
1
Centre Eugene Marquis, Rennes, France, 2CHU de Grenoble, Grenoble, France, 3Laboratoires Roche, Boulogne Billancourt,
France, 4Hôpital Saint-Louis, Paris, France
P072 Early follow-up of vemurafenib+cobimetinib combination therapy in 13 melanoma patients:
a Roche pre-approval access program in Hungary
Gorka E.1, Czirbesz K.1, Imredi E.1, Panczel G.1, Liszkay G.1
National Institute of Oncology, Dermatooncology, Budapest, Hungary
1
SCIENTIFIC PROGRAM
1
P073 Correlation between vitiligo and clinical outcome in patient with advanced melanoma
treated with nivolumab
Nakamura Y.1, Asami Y.1, Tanaka R.2, Teramoto Y.1, Imamura T.1, Sato S.1, Maruyama H.2, Fujisawa Y.2,
Fujimoto M.2, Yamamoto A.1
Saitama Medical University International Medical Center, Skin Oncology/Dermatology, Hidaka, Japan,
University of Tsukuba, Dermatology, Tsukuba, Japan
1
THU
WED
P074 Follow-up atypical melanocytic lesions with Dermato fluoroscopy: Rapid malignant
degeneration,
stable state or repair
Scholz M.1, Leupold D.2, Szyc L.2, Stankovic G.2, Pfeifer L.1, Buder S.3, Giering H.‑G.2
LTB Lasertechnik Berlin GmbH, Berlin, Germany, 2Magnosco GmbH, Berlin, Germany, 3Vivantes Klinikum Berlin Region
Süd, Klinik für Dermatologie und Venerologie, Berlin, Germany
1
SAT
FRI
P075 Multiple primary melanomas in a 59-years-old patient with xeroderma pigmentosum,
with a follow-up of 36 years
Abeldaño A.1, Arias M.1, Gonzalez A.2, Cinque Z.1, Romero Costa L.1, Benedetti A.1, Maskin M.1,
Rothlin A.1
Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina,
Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
1
P076 Lack of vitamin D toxicity in a longterm high dose vitamin D supplementation study for
cutaneous malignant melanoma (CMM)
De Smedt J.1, Van Kelst S.1, Van Eecke L.1, Vanderschueren D.2, Pauwels S.3, Billen J.3, Vandenberghe K.4,
Nikkels A.5, Garmyn M.1
Catholic University Leuven, Dermatology, Leuven, Belgium, 2Catholic University Leuven, Endocrinology, Leuven,
Belgium, 3Catholic University Leuven, Laboratory medicine, Leuven, Belgium, 4Catholic University Leuven, Cardiology,
Leuven, Belgium, 5Centre Hospitalier Universitaire de Liège, Dermatology, Liege, Belgium
1
P077 Significance of CT scans in melanoma surveillance – 10 year retrospective, single center
experience
Lengyel Z.1, Pozsgai M.1, Németh K.1, Gyulai R.1
University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary
1
65
INDEX
2
POSTER
MELANOMA
2
Scientific Program
Poster Exhibition
SCIENTIFIC PROGRAM
P078 The effect of psycho-educational interventions on health outcomes in individuals at increased
risk for melanoma: A systematic review of randomized controlled trials
Coroiu A.1, Moran C.2, Rice D.3, Kinglsland E.4, Thombs B.5,6, Korner A.1
1
McGill University, Educational and Counselling Psychology, Montreal, Canada, 2University of Ottawa, Psychology,
Ottawa, Canada, 3McGill University, Psychology, Montreal, Canada, 4McGill University, Humanities and Social Sciences
Library, Montreal, Canada, 5McGill University, Psychiatry, Montreal, Canada, 6Jewish General Hospital, Montreal, Canada
P079 Maligant melanoma masquerading as benign dermatoses
Detrixhe A.1, Lebas E.1, Nikkels A.2
University of Liège, Dept of Dermatology, Liège, Belgium, 2CHU du Sart Tilman, Dermatology, Liège, Belgium
1
P080 Successful management of Lower eyelid melanoma
Kim J.M.1, Rhie J.W.1
Seoul St. Mary’s Hospital, Plastic surgery, Seocho-gu, Korea,
1
P081 Vitiligo and tumoral melanosis: signs of metastasis in a melanoma patient
Tan W.P.1, Yeo B.1, Chia H.Y.1, Cheng S.1, Heng Y.K.1, Lee J.1
National Skin Centre, Singapore, Singapore
National Institute of Oncology, Department of Dermatology, Budapest, Hungary
THU
1
P083 Malignant melanoma of unknown primary origin treated with negative pressure wound therapy
and punch graft
Kim M.S.1, Lee Y.S.1, Na C.H.1, Shin B.S.1
FRI
WED
P082 14 months progression free survival with Dabrafenib therapy without previous stereotactic
radiotherapy in a patient with Metastatic Melanoma
Imrédi E.1, Czirbesz K.1, Gorka E.1, Pánczél G.1, Lőrincz L.1, Liszkay G.1
P084 Conservative surgery for subungual in situ melanoma using Matriderm®
Campagnari M.1, Carneiro H.A.2, Jafelicci A.S.2, Gomes E.E.1, Bertolli E.1, Duprat Neto J.P.1
Chosun University Medical School, Department of Dermatology, Gwang-ju, Korea, Republic of
1
POSTER
INDEX
SAT
1
AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center, Surgical Oncology
Residence, São Paulo, Brazil
P085 Invasive malignant melanoma accompanied by leukoderma
Park B.J.1, Cheon D.U.1, Oh E.H.1, Shin J.M.1, Kim E.J.1, Ko J.Y.1, Ro Y.S.1, Kim J.E.1
Hanyang University College of Medicine, Dermatology, Seoul, Korea
1
P086 Pigmented epithelioid melanocytoma – report of two cases
Cozzani R.1, Ferrua C.1, Molinari N.1, Gorostidy S.2, Quildrian S.3, del Águila R.1
Instituto de Oncología Ágel H. Roffo, Dermatología, Ciudad Autonoma de Buenos Aires, Argentina, 2Instituto de
Oncología Ágel H. Roffo, Patología, Ciudad Autonoma de Buenos Aires, Argentina, 3Instituto de Oncología Ágel H. Roffo,
Cirugía de Partes Blandas, Ciudad Autonoma de Buenos Aires, Argentina
1
P087 Challenges in staging and surveillance of patients with Neurofibromatosis and cutaneous
malignant melanoma
Chew P.R.1, Toh V.V.1, Kotwal A.1
Castle Hill Hospital, Department of Plastic Surgery, Hull, United Kingdom
1
66
MELANOMA
1
Scientific Program
Poster Exhibition
P088 Superficial spreading melanoma detected during the examination of a cutaneous horn
Russu L.1, Sprincenatu C.2, Russu M.3, Carjaliu A.A.4
Bioderm Medical Center, Dermatology, Bucharest, Romania, 2Bioderm Medical Center, Bucharest, Romania,
Bio Medica, Dermatology, Bucharest, Romania, 4Colentina Clinical Hospital, Dermatology, Bucharest, Romania
1
3
SCIENTIFIC PROGRAM
P089 Sporotrichoid spread of amelanotic metastatic malignant melanoma
Shpadaruk V.1, Mc Kiernan M.2, Fox R.2, Faust G.1, Barbieri A.2, Woo P.N.2
University Hospitals of Leicester, Leicester, United Kingdom, 2Northampton Hospital, Northampton, United Kingdom
1
P090 Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect
the phenotype switch?
Haueis S.1, Kränzlin P.1, Cheng P.F.1, Mangana J.1, Dummer R.1, Goldinger S.M.1
University Hospital of Zurich, Dermatology, Zurich, Switzerland
1
P091 Multiple primary melanomas – a single centre retrospective study
Menzies S.1, Rowley S.2, Ormond P.1
St James’s Hospital, Dermatology, Dublin, Ireland, 2St James’s Hospital, Dublin, Ireland
1
THU
P093 Melanoma patient support – what does your patient want?
Mowbray M.1, Fraser S.2, Hancock E.2, Scorgie C.2
WED
1
Magnosco GmbH, Berlin, Germany, 2Universitätsklinik Würzburg, Zentrum für Seelische Gesundheit, Klinik und Poliklinik
für Psychiatrie, Psychosomatik und Psychotherapie, Würzburg, Germany, 3Universität Würzburg, Pathologisches Institut,
Abteilung für Neuropathology, Würzburg, Germany, 4Alexianer St. Joseph-Krankenhaus, Klinik für Neurologie, Berlin,
Germany
NHS Fife, Scotland, Dermatology Department, Queen Margaret Hospital, Dunfermline, United Kingdom, 2NHS Fife,
Scotland, Dunfermline, United Kingdom
Medscape Education, New York, United States, 2Society for Immunotherapy of Cancer, Milwaukee, United States,
University of Chicago, Chicago, United States, 4New York University Medical Center, New York, United States
1
SAT
P095 Cancer immunotherapies in metastatic melanoma: effectiveness of unique case-based education
on clinical decision-making
Repetto P.1, Herrmann T.1, Warren C.1, Kadkhoda H.1, Scorzo M.2, Wiggins L.2, Luke J.3, Weber J.4
FRI
1
INDEX
3
P096 My cancer plan: An information App for patients in a cancer diagnostics programme
Holm J.1, Eldon M.1, Stolle L.B.1
Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark
1
POSTER
MELANOMA
P092 Increased risk of melanoma without pigmentation change. Results of Dermato fluoroscopy
of Parkinsonians
Leupold D.1, Stankovic G.1, Riederer P.2, Monoranu C.M.3, Müller T.4
P097 Malignant melanoma, is dominant at the ends: about a new observation acral
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
1
P098 Malignant melanoma and psoriasis acrolentigineux
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
1
P099 Malignant melanoma lumbar and psoriasis
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
1
67
Scientific Program
Poster Exhibition
P100 The prevalence of actinic keratosis and basal cell carcinoma and their association with UV
radiation in the elderly Latvian population
Balcere A.1,2, Karls R.1
P101 Merkel cell carcinoma in Franconia: Data on disease characteristics, treatment, and survival
Kirchberger M.C.1, Schuler G.1, Leonhardt U.1, Hofmann L.1, Meyer M.2, Heinzerling L.1
1
University Hospital Erlangen, Department of Dermatology, Erlangen, Germany, 2Centre for Early Cancer Detection and
Cancer Registration, Bavarian Health and Food Safety Authority, Nuremberg, Germany
P102 CD47 expression in non-melanoma skin cancers
Abbas O.1, Kurban M.1
American University of Beirut Medical Center, Dermatology, Beirut, Lebanon
1
P103 A mutual mr21-thyroid hormone interplay regulates skin tumorigenesis and BCC formation
Di Girolamo D.1, Ambrosio R.1, De Stefano M.A.1, Mancino G.1, Miro C.1, De Cicco E.1, Missero C.2,
Salvatore D.1, Dentice M.1
P104 Frequent loss of function mutations in TGFβR1 and TGFβR2 implicate hair follicle bulge stem cells
as a cell of origin of cutaneous squamous cell carcinoma
Cammareri P.1, Rose A.2, Vincent D.1, Wang J.3, Nagano A.3, Libertini S.1, Ridgway R.1, Mchugh A.2,
Pourreyon C.2, Spender L.2, Sapkota G.4, Purdie K.3, Proby C.2, Harwood C.3, Leigh I.2, Barker N.5,
Karlsson S.6, Pritchard C.7, Marais R.8, Chelala C.3, South A.9, Sansom O.1, Inman G.2
1
Cancer Research UK Beatson Institute, Glasgow, United Kingdom, 2University of Dundee, Division of Cancer Research,
Dundee, United Kingdom, 3Queen Mary University of London, Barts and The London School of Medicine and Dentistry,
London, United Kingdom, 4University of Dundee, Dundee, United Kingdom, 5Institute of Medical Biology, Singapore,
Singapore, 6Lund University, Lund, Sweden, 7University of Leicester, Leicester, United Kingdom, 8CRUK Manchester
Institute, Manchester, United Kingdom, 9Thomas Jefferson University, Philadelphia, United States
P105 Cooperation of Langerhans cells and NK cells guarding the epidermis during chemical
carcinogenesis
Ortner D.1, Tripp C.1, Komenda K.1, Dubrac S.1, Zelger B.1, Doppler W.2, Tymoszuk P.3, Boon L.4,
Clausen B.5, Stoitzner P.1
POSTER
INDEX
SAT
FRI
THU
WED
1
University of Naples Federico II, Clinical Medicine and Surgery, Naples, Italy, 2University of Naples “Federico II”, Biology,
Naples, Italy
Medical University Innsbruck, Department of Dermatology, Venereology & Allergology, Innsbruck, Austria, 2Medical
University Innsbruck, Section for Medical Biochemistry, Innsbruck, Austria, 3Medical University Innsbruck, Department of
Internal Medicine VI, Innsbruck, Austria, 4Bioceros, Utrecht, Netherlands, 5Medical Center of the Johannes GutenbergUniversity Mainz, Institute for Molecular Medicine, Mainz, Germany
1
P107 K36H protects skin from photocarcinogenesis via Bax/Bcl-2 and caspase dependent signaling
pathway in human epidermal keratinocytes
Lyu J.‑L.1, Chu Y.1, Lin P.1, Wu J.‑S.1, Huang Y.‑H.1, Shu W.‑G.1, Wen K.‑C.1, Chiang H.‑M.1, Kuo Y.‑H.2,3
1
China Medical University, Department of Cosmeceutics, Taichung, Taiwan, Republic of China, 2China Medical University,
Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, Taichung, Taiwan, Republic of China,
3
Asia University, Department of Biotechnology, Taichung, Taiwan, Republic of China
68
NON-MELANOMA SKIN CANCER
SCIENTIFIC PROGRAM
1
Riga Stradiņš University, Department of Infectology and Dermatology, Riga, Latvia, 2University of Latvia, Department of
Dermatovenerology, Riga, Latvia
Scientific Program
Poster Exhibition
P108 Minichromosome maintenance protein expression in squamous cell carcinoma
Stojkovic‑Filipovic J.1, Brasanac D.2, Bosic M.2, Lekic B.3
Clinic of Dermatovenereology, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia,
Institute of Pathology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia, 3Clinic of Dermatovenereology,
Clinical Center of Serbia, Belgrade, Serbia
1
P109 A reduction in endogenous transforming growth factor-β signalling independently predicts
increased tumour depth in human cutaneous squamous cell carcinoma
Rose A.1, Stephen C.2, Mitchell A.3, Rickaby W.4, Coates P.5, Proby C.6, Inman G.6
University of Dundee, Division of Cancer Research and Plastic and Reconstructive Surgery, Dundee, United Kingdom,
NHS Tayside, Plastic and Reconstructive Surgery, Dundee, United Kingdom, 3NHS Tayside, Department of Dermatology,
Dundee, United Kingdom, 4St.Johns Institute of Dermatology, Dermatopathology, London, United Kingdom, 5Masaryk
Memorial Cancer Institute, Regional Centre for Applied Molecular Oncology (RECAMO), Brno, Czech Republic, 6University
of Dundee, Division of Cancer Research, Dundee, United Kingdom
1
2
P110
Mid-face location of primary basal cell carcinoma related to the aggressiveness of the cancer
Mawardi P.1,2, Kalim H.2, Kalim K.2, Enggar Fitri L.2, Mudigdo A.3, Wasita B.3, Oyong O.4
SCIENTIFIC PROGRAM
2
Sebelas Maret University/Dr. Moewardi Hospital, Dermatovenereology Department, Surakarta, Indonesia, 2Brawijaya
University, Faculty of Medicine, Malang, Indonesia, 3Sebelas Maret University/Dr. Moewardi Hospital, Pathology
Department, Surakarta, Indonesia, 4Sebelas Maret University/Dr. Moewardi Hospital, Faculty of Medicine, Surakarta,
Indonesia
A Danish Cancer Center retrospective study on frozen section excisions of non-melanoma skin
cancer in 2015
Holm J.1, Barnkob S.1, Kjerkegaard U.K.1, Stolle L.B.1
WED
P111
Vejle Hospital, Odense University Hospital, Department of Plastic Surgery, Vejle, Denmark
Skin adnexal neoplasms: a real diagnosis challenge
Kelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.1
1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan
II, Anatomopathology, Fez, Morocco
Malignant adnexal neoplasms: Moroccan experience
Kelati A.1, Tahiri L.2, Harmouch T.2, Mernissi F.Z.1
SAT
P113
FRI
P112
THU
1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco,
Faculty of Medicine, Hospital Hassan II, Anatomopathology, Fez, Morocco
1
2
Dermoscopy of scalp BCC: variability according to clinical features and anatomic sub-site
Suppa M.1, Sollena P.2, Micantonio T.3, Longo C.4, Fargnoli M.C.3, Peris K.2
INDEX
P114
Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2Catholic University of
the Sacred Heart, Department of Dermatology, Rome, Italy, 3University of L’Aquila, Department of Dermatology, L’Aquila,
Italy, 4Arcispedale S. Maria Nuova-IRCCS, Dermatology and Skin Cancer, Reggio Emilia, Italy
1
P115
Characterisation of the molecular landscape of cutaneous squamous cell carcinoma
Proby C.1, Inman G.1, Wang J.2, Nagano A.2, Purdie K.3, Mladkova N.3, Lambert S.3,
Gulati A.3, Sherwood V.1, Saville M.1, Chelala C.2, Harwood C.3, Leigh I.1,4,
Cancer Research UK Skin Tumour Laboratory
University of Dundee, Ninewells Hospital, Division of Cancer Research, College of Medicine, Dundee, United Kingdom,
Barts Cancer Institute, Queen Mary University of London, Bioinformatics Unit, London, United Kingdom, 3Blizzard
Institute, Queen Mary University of London, Centre for Cutaneous Research, London, United Kingdom, 4Barts Cancer
Institute, Queen Mary University of London, Centre for Tumour Biology, London, United Kingdom
1
2
69
POSTER
NON-MELANOMA SKIN CANCER
1
Scientific Program
P116
Poster Exhibition
The use of liquid-based cytology in diagnostics of basal cell carcinoma and actinic keratosis
Christensen E.1, Eriksen Malone Isham S.2
SCIENTIFIC PROGRAM
1
St. Olav’s University Hospital and Norwegian University of Science and Technology (NTNU),
Department of Dermatology, and Department of Cancer Research and Molecular Medicine, Trondheim, Norway,
2
St. Olavs University Hospital, Department of Medicine, Trondheim, Norway
P118
miRNAs as potential players RDEB cancer development
Wimmer M.1, Zauner R.1, Lettner T.1, Niklas N.2, Pröll J.2, Bauer J.W.1, Reichelt J.1, Wally V.1
1
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University
Hospital of the Paracelsus Medical University Salzburg, Salzburg, Austria, 2Red Cross Transfusion Service for Upper
Austria, Linz, Austria
P119
The effects of Cxcl1 antagonist on UVB-induced skin inflammation in Xeroderma pigmentosum
type A deficient mice
Kunisada M.1, Hosaka C.1, Nakano E.1, Enomoto H.2, Nishigori C.1
Kobe University of Medicine, Dermatology, Kobe, Japan, 2Kobe University of Medicine, Division of Neural Differentiation
and Regeneration, Department of Physiology and Cell Biology, Kobe, Japan
P120 5-fluorouracil loaded liposomes targeted with cetuximab inhibit skin squamous cell carcinoma
in xenograft animal model
Petrilli R.1,2, Eloy J.O.1,2, Lee R.J.2, Lopez R.F.V.1
College of Pharmaceutical Sciences of Ribeirão Preto – University of Sao Paulo (USP), Ribeirao Preto, Brazil,
College of Pharmacy – The Ohio State University (OSU), Columbus, United States
WED
1
2
THU
P121
FRI
1
Hopital Saint-Louis, Paris, France, 2Centre d’Oncodermatologie
CLCC/CHU de Rennes, Rennes, France, 3Hôpital Ambroise Paré, Boulogne Billancourt, France, 4CHU de Dijon, Dijon, France,
5
CHU de Montpellier, Montpellier, France, 6Institut Gustave Roussy, Villejuif, France, 7CHU de Grenoble, Grenoble, France,
8
CHRU de Lille, Lille, France, 9Centre Oscar Lambret, Lille, France, 10Laboratoires Roche, Boulogne Billancourt, France
SAT
INDEX
POSTER
VISMONEO – a phase II study assessing vismodegib in the neoadjuvant treatment of locally
advanced basal cell carcinoma – patients characteristics
Basset‑Seguin N.1, Dupuy A.2, Saiag P.3, Dalac‑Rat S.4, Guillot B.5, Routier E.6, Leccia M.T.7, Duhamel A.8,
Mirabel X.9, Benbouta I.8, Mirakovska L.8, Meddour D.8, Dib M.8, Mahmoudi A.10, Guerreschi P.8,
Mortier L.8
P122 Health-Related Quality of Life (HRQoL) analysis by skindex-16 in MIKIE, a randomized phase 2
study to assess the efficacy and safety of two intermittent Vismodegib (VISMO) regimens in
patients (pts) with multiple basal cell Carcinomas (BCCs)
Dréno B.1, Hauschild A.2, Maher I.3, Zloty D.4, Labeille B.5, Grob J.‑J.6, Puig S.7, Karagiannis T.8,
Gilberg F.9, Schadendorf D.10, Kunstfeld R.11, Rogers G.12
1
Nantes University, Nantes, France, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Saint Louis University
Medical School, St. Louis, United States, 4University of British Columbia, Vancouver, Canada, 5University Hospital of
Saint-Etienne, Saint-Etienne, France, 6Timone Hospital, Marseille, France, 7Hospital Clinic de Barcelona, Barcelona, Spain,
8
Genentech, Inc., South San Francisco, United States, 9Hoffman-La Roche, Ltd, Basel, Switzerland, 10Universitätsklinikum
Essen, Essen, Germany, 11Medical University of Vienna, Vienna, Austria, 12Tufts University School of Medicine, Boston,
United States
70
NON-MELANOMA SKIN CANCER
1
Scientific Program
Poster Exhibition
P123 Sonidegib safety in patients with locally advanced Basal Cell Carcinoma and efficacy
based on tumor aggressiveness
Lear J.1, Guminski A.2, Gutzmer R.3, Migden M.4, Kudchadkar R.5, Lewis K.6, Dirix L.7, Plummer R.8,
Stratigos A.9, Chang A.L.10, Trefzer U.11, Loquai C.12, Kaatz M.13, Combemale P.14, Mone M.15, Castro H.16,
Yi T.15, Sellami D.15, Dummer R.17
Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Royal North
Shore Hospital, St Leonards, Australia, 3Medizinische Hochschule Hannover, Hannover, Germany, 4The University of
Texas MD Anderson Cancer Center, Houston, United States, 5Winship Cancer Institute of Emory University, Atlanta,
United States, 6University of Colorado Cancer Center, Aurora, United States, 7Sint-Augustinus Ziekenhuis, Antwerp,
Belgium, 8Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 9Andreas Syggros
Hospital, University of Athens, Athens, Greece, 10Stanford University School of Medicine, Redwood City, United States,
11
Dermatologikum Berlin, Berlin, Germany, 12University Medical Center Mainz, Mainz, Germany, 13University Hospital
Jena, Jena, Germany, 14Centre Leon Bérard, Lyon, France, 15Novartis Pharmaceuticals Corporation, East Hanover, United
States, 16Novartis Pharma AG, Basel, Switzerland, 17UniversitätsSpital Zürich, Skin Cancer Center, University Hospital,
Zürich, Switzerland
SCIENTIFIC PROGRAM
1
P124 Sclerodermiform basal cell carcinoma and surgical treatment. Where is the surgery limit?
Ciudad Blanco C.1, Parra Blanco V.2, Suárez Fernández R.1
Hospital General Universitario Gregorio Marañón, Dermatology, Madrid, Spain, 2Hospital General Universitario Gregorio
Marañón, Pathology, Madrid, Spain
Utilising intraoperative frozen section in the surgical management of patients with nonmelanocytic skin cancer improve outcomes
Teng T.Y.1, Chia J.C.H.2, Hing E.C.H.1, Ong W.C.1, Lim J.1, Lim T.C.1, Yap Y.L.1
WED
P126
Division of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore,
University of Sydney, Sydney, Australia
1
P127
THU
2
Successful use of grenz rays for DSAP: Report of 8 cases
Ramelyte E.1,2, Bylaite‑Bucinskiene M.2, Dummer R.1, Imhof L.1
FRI
1
University Hospital Zurich, Dermatology, Zurich, Switzerland, 2Vilnius University, Dermatovenereology, Vilnius,
Lithuania
SAT
P128 A versatile flap for reconstruction of partial pinna defects after tumour resection –
The pre-auricular flap
Jayarajan R.1, Agarwal R.1
University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom
INDEX
1
P129 Long-term follow-up of two patients with Nevoid basal cell carcinoma syndrome (NBCCS)
treated with Vismodegib
Van Eecke L.1, Wolter P.2, Bechter O.2, Rogiers A.2, De Smedt J.1, Garmyn M.1
POSTER
NON-MELANOMA SKIN CANCER
1
UZLeuven, Dermatology, Leuven, Belgium, 2UZLeuven, Oncology, Leuven, Belgium
1
P130 Erythroplasia of Queyrat (EQ): a diagnostic and therapeutic challenge
Drljevic I.1, Dajic Hrvanovic S.2
1
University of Zenica, Faculty of Health, Private Clinic for Dermatovenereology ‘Dr Drljevic’, Sarajevo, Bosnia
and Herzegovina, 2Cantonal Hospital Zenica, Dermatovenereology Department, Zenica, Bosnia and Herzegovina
P131
Prospective randomised control trial comparing electrochemotherapy and surgery for the
primary treatment of basal cell carcinoma
Clover A.J.1, Salwa S.2, McKiernan J.1, Buckley C.1, Bourke M.2, Kelly E.J.1, O’Sullivan S.1, Soden D.M.2
University College Cork, Department of Plastic Surgery, Cork, Ireland, 2University College Cork, Cork Cancer Research
Centre, Cork, Ireland
1
71
Scientific Program
P133
European Medical Center, Moscow, Russian Federation
1
Medical University of Vienna, Vienna, Austria, 2University of British Columbia, Vancouver, Canada, 3Stanford University,
La Jolla, United States, 4Hôpital Saint Louis, Paris, France, 5Innovaderm Research, Inc., Montreal, Canada, 6Aix-Marseille
University, Hopital Timone APHM, Marseille, France, 7Saint Louis University Medical School, St. Louis, United States,
8
Hoffman-La Roche, Ltd, Basel, Switzerland, 9Nantes University, Nantes, France, 10Tufts University School of Medicine,
Boston, United States, 11Universitätsklinikum Essen, Essen, Germany
P135
Development of muscle spasm during Vismodegib treatment and the effect of treatment
interruptions: exploratory analyses from the STEVIE study
Kunstfeld R.1, Hauschild A.2, Basset‑Séguin N.3, Hansson J.4, Dréno B.5, Mortier L.6, Ascierto P.7,
Licitra L.8, Dimier N.9, Xynos I.9, Grob J.‑J.10
Medical University of Vienna, Vienna, Austria, 2University Hospital Schleswig-Holstein, Kiel, Germany, 3Hôpital Saint
Louis, Paris, France, 4Karolinska University Hospital, Solna, Stockholm, Sweden, 5Nantes University, Nantes, France,
6
University of Lille 2, Lille Regional University Hospital, Lille, France, 7Istituto Nazionale Tumori Fondazione G. Pascale,
Naples, Italy, 8Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, 9Roche Products, Ltd., Welwyn Garden City,
United Kingdom, 10Aix-Marseille University, Hopital Timone APHM, Marseille, France
1
P136 A randomized split-face clinical trial of daylight photodynamic therapy with methyl
aminolaevulinate vs ingenol mebutate gel for the treatment of actinic keratosis of the face
and scalp
Calzavara‑Pinton P.1, Moggio E.2, Arisi M.2, Zane C.1
University of Brescia, Brescia, Italy, 2University of Brescia, Dermatology, Brescia, Italy
1
P137
Clinical care of actinic keratoses: Documentation of number and treatment modalities in a case
register project in Germany
Leiter U.1, Weichenthal M.2
University of Tuebingen, Dermatology, Tuebingen, Germany, 2University of Kiel, Dermatology, Kiel, Germany
1
P138 Ingenol mebutate versus daylight methyl-aminolevulinate photodynamic therapy for the
treatment of actinic keratoses: an intraindividual comparative analysis
Fai D.1, Mavilia L.2, Genovese G.2, Fai C.1
Daniele Romasi Hospital, Dermatology, Gagliano del Capo, Italy, 2San Raffaele, Dermatology, Milano, Italy
1
72
NON-MELANOMA SKIN CANCER
P134 Analysis of patients (pts) with and without basal cell carcinoma nevus syndrome (BCCNS)
in MIKIE, a randomized phase 2 study to assess the efficacy and safety of two intermittent
Vismodegib (VISMO) regimens in pts with multiple Basal Cell Carcinomas (BCCs)
Kunstfeld R.1, Zloty D.2, Tang J.3, Basset‑Séguin N.4, Bissonnette R.5, Grob J.‑J.6, Maher I.7,
Bergström D.8, Gilberg F.8, Dréno B.9, Rogers G.10, Schadendorf D.11
FRI
THU
Photodynamic therapy with methylaminolevulinate (MAL-PDT) for superficial and nodular basal
cell carcinoma (BCC): clinical study
Dzybova E.1, Vasilevskaya E.1, Vardanyan K.1, Potekaev N.1
1
SAT
INDEX
POSTER
Targeting tumor metabolism in the therapy of aggressive squamous cell carcinoma in patients
with epidermolysis bullosa
Welponer T.1, Piñón Hofbauer J.1, Gruber C.1, Kienzl M.1, Aminzadeh‑Gohari S.2, Feichtinger R.2,
Lang R.1, Bauer J.W.3, Kofler B.2, Reichelt J.1
1
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, Paracelsus
Medical University, Salzburg, Austria, 2Laura Bassi Centre of Expertise-THERAPEP, Research Program for Receptor
Biochemistry and Tumor Metabolism, Department of Pediatrics, Paracelsus Medical University, Salzburg, Austria,
3
Department of Dermatology, Paracelsus Medical University, Salzburg, Austria
WED
SCIENTIFIC PROGRAM
P132
Poster Exhibition
Scientific Program
P139
Poster Exhibition
Daylight photodynamic therapy with methyl aminolevulinate cream versus diclofenac plus
hyaluronic acid gel for the treatment of multiple actinic keratoses: An indirect comparison
Calzavara‑Pinton P.1, Zane C.1, Pacou M.2, Szeimies R.‑M.3
University of Brescia, Department of Dermatology, Brescia, Italy, 2Amaris, Paris, France, 3Klinikum Vest GmbH Academic
Teaching Hospital, Dept. of Dermatology and Allergology, Recklinghausen, Germany
1
P141
SCIENTIFIC PROGRAM
P140 Adapting a UV-induced skin carcinogenesis model in immunocompetent SKH1 mice to
therapeutic testing of compounds against skin cancer
Christensen P.1, Høyer‑Hansen M.H.1, Skak K.1
1
LEO Pharma, Ballerup, Denmark
Photodynamic therapy with methylaminolevulinate (MAL-PDT) for actinic keratosis (AK):
clinical study
Dzybova E.1, Vasilevskaya E.1, Potekaev N.1, Vardanyan K.1
European Medical Center, Moscow, Russian Federation
1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco
1
P143 Actinic keratosis induces angiogenesis
Valero T.1, Neumüller K.2, Krall C.3, Petzelbauer P.1
Medical University Vienna, Department of Dermatology, Vienna, Austria, 2Medical University Vienna, Skin &
Endothelium Research Division (SERD), Vienna, Austria, 3Medical University Vienna, Institute of Medical Statistics,
Vienna, Austria
WED
1
THU
P144 The role of histological verification of metastases in onco-dermatology
Pánczél G.1, Plótár V.2, Bőcs K.3, Liszkay G.1
National Institute of Oncology, Oncodermatology, Budapest, Hungary, 2National Institute of Oncology, Molecular
Pathology, Budapest, Hungary, 3National Institute of Oncology, Diagnostic Radiology, Budapest, Hungary
FRI
1
Aristotle University, First Dermatology Department, Thessaloniki, Greece
1
P146 Basal Cell Carcinoma: Smartphone app control vs. clinical control
Eldon M.1, Hedelund L.1, Lorentzen H.F.1, Thormann H.2, Bjørn Stolle L.3
Aarhus University Hospital, Department of Dermatology, Aarhus, Denmark, 2Odense University Hospital, Private Practice
Dermatologist, Vejle, Denmark, 3Odense University Hospital, Department of Plastic Surgery, Odense, Denmark
1
P147
Postoperative risk factors of organ transplant recipients following dermatosurgical procedures
Kröpfl L.1, Schadendorf D.2, Hillen U.2, Klode J.2
Praxis Buljanovic-Kröpfl, Dermatologie, Essen, Germany, 2Universitätsklinikum Essen, Dermatologie, Essen, Germany
1
P148 Chronic radiation dermatitis induced by radiotherapy associated with cisplatin in a case
of hypopharyngeal cancer
Jerkovic Gulin S.1, Chiriac A.2
General Hospital Sibenik, 1 Department of Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia,
Dermatology Department, Nicolina Medical Centre, Apollonia University, „P.Poni“ Research Institute of Macromolecular
Chemistry, Iasi, Romania
1
2
73
INDEX
SAT
P145 Conventional PDT vs fractional CO2 laser-assisted-PDT with short incubation time in skin cancer
prevention: a randomized intraindividual comparison study with 12-month follow-up
Vrani F.1, Sotiriou E.1, Vakirlis E.1, Lazaridou E.1, Ioannides D.1
POSTER
NON-MELANOMA SKIN CANCER
P142 What’s new in the dermoscopy of actinic keratosis? A study of 232 cases
Kelati A.1, Mernissi F.Z.1
Scientific Program
Poster Exhibition
P149 Basal cell carcinoma axillary: about 02 cases
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
SCIENTIFIC PROGRAM
1
P150 Dermal substitutes in cutaneous oncology: A single center experience
Campagnari M.1, Jafelicci A.S.2, Carneiro H.A.2, Brechtbühl E.R.1, Bertolli E.1, Duprat Neto J.P.1
1
AC Camargo Cancer Center, Skin Cancer Department, São Paulo, Brazil, 2AC Camargo Cancer Center,
Surgical Oncology Residence, São Paulo, Brazil
P151
A rare case of basal cell carcinoma of the face associated with parotid in-transit metastasis
Teng T.Y.1, Xu X.1, Nallathamby V.1, Yap Y.L.1, Lim J.1, Lim T.C.1, Ong W.C.1
Divison of Plastic, Reconstructive and Aesthetic Surgery, National University Health System, Singapore, Singapore
1
P152
Two cases of squamous cell carcinoma associated with seborrhoeic keratoses
Tan W.P.1, Lim C.1, Tee S.I.1
National Skin Centre, Singapore, Singapore
P153
Weekly cisplatin, epirubicin, and paclitaxel induced a durable response
in two cases of metastatic extramammary Paget’s disease
Hirai I.1, Funakoshi T.1
Keio University School of Medicine, Dermatology, Tokyo, Japan
WED
1
P154 An unexpected diagnosis of a chronic ulcer on lower extremity
Açıkgöz G.1, Küçük K.1, Kılınç M.2
Gülhane School of Military Medicine, Dermatology, Ankara, Turkey, 2Gülhane School of Military Medicine, Pathology AD,
Ankara, Turkey
P155
SAT
INDEX
POSTER
Gorlin syndrome with locally advanced basal cell carcinomas treated with vismodegib
Abeldaño A.1, Maskin M.1, Arias M.1, Gonzalez A.2, Benedetti A.1, Lamas C.1
Hospital Gral. de Agudos Dr. Cosme Argerich. Universidad de Buenos Aires, Buenos Aires, Argentina,
Hospital Dr. Angel Roffo, Universidad de Buenos Aires, Buenos Aires, Argentina
1
FRI
THU
1
2
P156 Primary cutaneous mucinous adenocarcinoma: sex hormone receptors a clue to the aetiology
Tang H.K.C.1, Housa D.2, Patel G.K.1
Prince Philip Hospital, Dermatology, Llanelli, United Kingdom, 2Prince Philip Hospital, Pathology, Llanelli, United Kingdom
1
P157
The rate and pattern of metastasis from head & neck cutaneous squamous cell carcinoma
Ainscough S.1, Brown N.2
York Teaching Hospitals, Head & Neck, York, United Kingdom, 2York Teaching Hospitals, York, United Kingdom
1
P158 Dermatofibrosarcoma protuberans: diagnosis, treatment and follow-up of a case series of 8 patients
Pavlova E.1, Stanimirov P.2, Slavkova S.3, Troyanova P.1
University Hospital Tsaritsa Yoanna-ISUL, Outpatient Department, Sofia, Bulgaria, 2University Hospital Alexandrovska,
Department of Maxillo Facial Surgery, Sofia, Bulgaria, 3HELIOS Vogtland-Klinikum Plauen, Department of Dermatology
and Allergology, Plauen, Germany
1
P159
Overgrowth of undifferentiated pleomorphic sarcoma during vismodegib treatment of locally
advanced basal cell carcinoma – a case report
Mijuskovic Z.P.1, Brasanac D.2, Sijan G.3, Rajovic M.3, Kandolf‑Sekulovic L.1
Faculty of Medicine, Military Medical Academy, Clinic of Dermatology and Venereology, Belgrade, Serbia, 2Faculty
of Medicine, University of Belgrade, Institute of Pathology, Belgrade, Serbia, 3Faculty of Medicine, Military Medical
Academy, Clinic of Plastic Surgery and Burns, Belgrade, Serbia
1
74
NON-MELANOMA SKIN CANCER
1
Scientific Program
Poster Exhibition
1
University Hospital Centre Zagreb, School of Medicine University of Zagreb, Department of Dermatology and
Venereology, Zagreb, Croatia, 2The Academy of Medical Sciences of Croatia, Zagreb, Croatia, 3University Hospital Centre
Zagreb, Department of Pathology and Cytology, Zagreb, Croatia, 4Clinical Hospital ‘Sveti Duh’ Zagreb, Department of
Pathology and Cytology, Zagreb, Croatia
P161
Characteristic of immune status of patients with basal cell carcinoma (BCC), who live in the industrial
district with the highest incidence of “non-melanoma skin cancers” (NMSC) in South Ural
Pisklakova T.1, Ekimova O.2
1
South Ural State University, Department of Service and Technologies of Art Processing Materials, Chelyabinsk, Russian
Federation, 2Regional Dermatology and Venereology Clinic № 3, Outpatient Department, Chelyabinsk, Russian Federation
P162 Lymphomatoid papulosis type D: do not ignore this entity and not to be confused
with aggressive lymphoma CD8
Boudghene Stambouli O.1
SCIENTIFIC PROGRAM
P160 Expression of HER family of tyrosine kynase receptors, proliferation marker Ki67 and protein p53
in multiple and solitary cutaneous squamous cell carcinoma
Ledic Drvar D.1, Lipozencic J.2, Bukvic Mokos Z.1, Ilic I.3, Knezevic F.4
Faculty of Medicine, Dermatology, Tlemcen, Algeria
P163 Multiple giant warts (Buschke-Lowenstein tumor) with malignant transformation
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
WED
1
THU
P164 Non-melanoma skin cancer operative records – introduction of a proforma for complete
documentation
Jayarajan R.1, Ibrahim N.1, Sayed L.1
University Hospitals of Leicester, Plastic Surgery, Leicester, United Kingdom
1
FRI
P165 Keratoacanthoma-like metastasis as the presenting sign of lung carcinoma: a case report
Đurinec P.1, Radoš J.1, Kostović K.1, Ilić I.2, Marinović B.1
SAT
1
University of Zagreb School of Medicine, University Hospital Center Zagreb, Department of Dermatology and
Venereology, Zagreb, Croatia, 2University of Zagreb School of Medicine, University Hospital Center Zagreb, Department
of Pathology, Zagreb, Croatia
P166 Pigmented Bowen’s disease – how to recognize it? A case report
Rados J.1, Loncaric D.1, Zuzul K.1, Curkovic D.1, Marinovic B.1
UHC Zagreb and School of Medicine, University of Zagreb, Department of Dermatovenereology, Zagreb, Croatia
P167
INDEX
1
Microcystic adnexal carcinoma in atypical site (pubic region): clinic and dermatoscopy
Astorino S.1, Carelli G.2, Pasquini P.3
POSTER
NON-MELANOMA SKIN CANCER
1
Unit of Dermatology and s.t.d., ‘Celio’ Military Hospital, Rome, Italy, 2Army School of Health, Rome, Italy,
Histopathology Service, ‘Celio’ Military Hospital, Rome, Italy
1
3
P168 Merkel cell carcinoma of the trunk and extremities in Argentina
Cozzani R.1, Daffinoti A.2, Cervelo G.2, Gerino J.2, del Aguila R.1, Chapela J.2, Quildrian S.2
1
Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Dermatology, Ciudad Autonoma de Buenos Aires,
Argentina, 2Instituto de Oncología Ágel H. Roffo – University of Buenos Aires, Soft Tissue Tumors, Ciudad Autonoma de
Buenos Aires, Argentina
P169 Clinical behaviour of Merkel cell carcinoma- the York experience
Krishnan O.1, Brown J.1, Brown N.1
York Hospital, Oral & Maxillofacial Surgery, York, United Kingdom
1
75
Scientific Program
P170
Poster Exhibition
Diagnostic value of plasmacytoid dendritic cells in differentiating primary follicular mucinosis
(FM) from lymphoma-associated FM
Abbas O.1, Kurban M.1
American University of Beirut Medical Center, Dermatology, Beirut, Lebanon
SCIENTIFIC PROGRAM
1
P171
Biological properties of T-cell lymphoma (Mycosis fungoides) in correlation with the clinical
picture, stage and patient outcome in Croatia – ten-year follow-up
Jerkovic Gulin S.1, Ceovic R.2,3, Ilic I.4, Kostovic K.2,3, Marinovic B.2,3
1
General Hospital Sibenik, Infectious Diseases, Dermatology and Venereology, Sibenik, Croatia, 2University of Zagreb
School of Medicine, Zagreb, Croatia, 3University Hospital Center Zagreb, Department of Dermatology and Venereology,
Zagreb, Croatia, 4University Hospital Center Zagreb, Department of Pathology and Cytology, Zagreb, Croatia
P172 Defining the mimics and the clinico-histological diagnosis criteria for Mycosis fungoides
in order to minimize misdetection
Kelati A.1, Harmouch T.2, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco, 2Faculty of Medicine, Hospital Hassan
II, Anatomopathology, Fez, Morocco
P173 Cutaneous T cell infiltrates – Immunohistochemical and genomic issues
Proca Nicula A.1, Baderca F.2,3, Solovan C.1,2
University Clinic of Dermatology and Venereology, Timisoara, Romania, 2“Victor Babes” University of Medicine
and Pharmacy, Timisoara, Romania, 3Emergency City Hospital, Service of Pathology, Timisoara, Romania
P175
THU
WED
1
Clinical characteristics, risk factors and long-term outcome of 114 patients with folliculotropic
mycosis fungoides
Wieser I.1,2, Wang C.1, Alberti‑Violetti S.1, Lyons G.3, Tran C.4, Talpur R.1, Duvic M.1
FRI
1
The University of Texas M.D. Anderson Cancer Center, Dermatology, Houston, United States, 2Paracelsus Medical
University, Department of Dermatology, Salzburg, Austria, 3The University of Texas, MD Anderson Cancer Center,
Department of Biostatistics, Houston, United States, 4University of North Texas Health Science Center, Texas College
of Osteopathic Medicine, Fort Worth, United States
SAT
P176
Frequency increase, clinical features, and survival outcomes of cutaneous lymphoma in Morocco:
A subgroup analysis per 10-year period
Kelati A.1, Safae Z.1, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco
INDEX
1
P177 Frequency and risk factors for secondary malignancies in patients with mycosis fungoides
Cengiz F.P.1, Emiroglu N.1, Biyik Ozkaya D.1, Gulsel Bahali A.1, Su O.1, Onsun N.1
Bezmialem Vakif University, Dermatology and Veneorology, Istanbul, Turkey
POSTER
1
P178
Prognostic factors of patients with mycosis fungoides
Bahalı A.G.1, Su Ö.1, Cengiz F.P.1, Emiroğlu N.1, Bıyık Özkaya D.1, Onsun N.1
Bezmialem Vakif University, Dermatology, İstanbul, Turkey
1
P179
Long-term follow-up of benign course of lymphomatoid papulosis – a case report
Bartolić L.1, Jović A.2, Radoš J.2, Ilić I.3, Kostović K.2
Private Specialist of Dermatology and Venereology Practice Dr. Kedmenec Bartolić, Čakovec, Croatia,
University Hospital Center Zagreb, Department of Dermatology and Venereology, School of Medicine, Zagreb, Croatia,
University Hospital Center Zagreb, Department of Pathology, School of Medicine, Zagreb, Croatia
1
2
3
76
CUTANEOUS LYMPHOMA
1
Scientific Program
Poster Exhibition
P180 Periorbital involvement in early stage mycosis fungoides
Wieser I.1,2, Bush A.E.1, Dabaja B.S.3, Duvic M.1
The University of Texas M.D. Anderson Cancer Center, Department of Dermatology, Houston, United States, 2Department
of Dermatology, Paracelsus Medical University, Salzburg, Austria, 3The University of Texas M.D. Anderson Cancer Center,
Department of Radiation Oncology, Houston, United States
P181 Hypopigmented mycosis fungoides versus mycosis fungoides with concomitant hypopigmented
lesions: same disease or different variants of mycosis fungoides? Moroccan experience
Kelati A.1, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco
1
P182 Folliculotropic mycosis fungoides: clinical and histopathological features in a Moroccan patient
series
Kelati A.1, Zinoune S.2, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco,
Faculty of Medicine, Hospital Hassan II, Fez, Morocco
1
SCIENTIFIC PROGRAM
1
P183 An unusual case of palmoplantar eczema?
Mokbel R.1, Chinthapalli S.1, Rizvi H.1, Cerio R.1, Goldsmith P.1
Royal London Hospital, London, United Kingdom
1
WED
P184 Primary extramedullary plasmacytoma presenting as chronic ulcerative, whitish plaques
on the oral mucosa
Kim J.E.1, Han J.H.1, Woo Y.J.1, Kang H.1
St. Paul’s Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
1
THU
P185 Cutaneous T cell lymphoma in a patient with primary biliary cirrhosis
Guler Ozden M.1, Ayyıldızt T.2, Nilgün Ş.1, Tayyar C.1
Ondokuz Mayıs University Medical Faculty, Dermatology, Samsun, Turkey,
Ondokuz Mayıs University, Medical Faculty, Gastroenterology, Samsun, Turkey
1
FRI
2
P186 Cutaneous manifestations of haematologic malignancies – two case reports
Schmid M.A.1,2, Rainer G.1,2, Udvardi A.1,2, Birkner T.3, Chott A.4, Klapper W.5, Volc‑Platzer B.1,2
Donauspital SMZO, Department of Dermatology, Vienna, Austria, 2Karl Landsteiner Institute for Pediatric Dermatology,
Vienna, Austria, 3Donauspital SMZO, Institute of Pathology, Vienna, Austria, 4Wilhelminenspital, Institute of Pathology,
Vienna, Austria, 5University-Hospital Schleswig-Holstein, Department of Pathology, Kiel, Germany
INDEX
SAT
1
P187 Primary cutaneous CD30+ lymphoproliferative disorders: the beast or the beauty?
Kelati A.1, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco
1
POSTER
CUTANEOUS LYMPHOMA
2
P188 Plasmablastic lymphoma presenting in the skin: report of two clinical cases
Fernandes I.1, Cabral R.2, Mota F.3, Mesquita B.4, Selores M.3, Coutinho J.5, Lima M.2
1
Hospital de Santo António, Centro Hospitalar do Porto, Dermatology; Multidisciplinary Consultation for Cutaneous
Lymphomas and Mastocytosis, Porto, Portugal, 2Hospital de Santo António, Centro Hospitalar do Porto, Hematology;
Multidisciplinary Consultation for Cutaneous Lymphomas and Mastocytosis, Porto, Portugal, 3Hospital de Santo António,
Centro Hospitalar do Porto, Dermatology, Porto, Portugal, 4Hospital de Vila Real, Centro Hospitalar de Trás-os-Montes
e Alto Douro, Hematology, Porto, Portugal, 5Hospital de Santo António, Centro Hospitalar do Porto, Hematology, Porto,
Portugal
77
Scientific Program
Poster Exhibition
P189 Primary cutaneous lymphoma of 20 cases: CHU experience of Department of Dermatology
Tlemcen (West Algeria)
Boudghene Stambouli O.1, Nawel A.2
Faculty of Medicine University Aboubakr Belkaid, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University
Aboubakr Belkaid, Tlemcen, Algeria
SCIENTIFIC PROGRAM
1
P190 Mycosis fungoides in its pseudo leprous form of pigmented skin
Boudghene Stambouli O.1, Nawel A.2
1
Faculty of Medicine, Dermatology, Tlemcen, Algeria, 2Faculty of Medicine University Aboubakr Belkaid, Dermatology,
Tlemcen, Algeria
P191 Immune checkpoints in Merkel cell carcinoma
Wehkamp U.1, Stern S.1, Krüger S.2, Röcken C.2, Egberts F.1
University Hospital Schleswig-Holstein, Department of Dermatology, Kiel, Germany,
University Hospital Schleswig-Holstein, Institute of Pathology, Kiel, Germany
1
2
P192 Evaluation of the immunogenicity of viral epitopes in a cancer immunogene therapy approach
for squamous cell carcinoma in RDEB
Reichl V.M.1, Kienzl M.1, Stöcklinger A.2, Tockner B.1, Reichelt J.1, Gruber C.1, Pinon‑Hofbauer J.1
P193 Nodular fasciitis: an underdiagnosed entity
Ferrario D.1, Luna A.1, Molinari L.1, Rodriguez Kowalczuc M.V.1, Volonteri V.1, Galimberti G.1
Hospital Italiano, Buenos Aires, Argentina
POSTER
INDEX
SAT
FRI
THU
1
P194 Solitary cutaneous metastasis of renal clear cell carcinoma on nasal tip
Gómez‑Zubiaur A.1, Trasobares‑Marugán L.1, Aboín‑González S.1, Medina‑Expósito I.2,
Villalobos‑León M.L.3
Príncipe de Asturias Hospital, University of Alcalá, Dermatology and Venereology Department, Alcalá de Henares,
Spain, 2Príncipe de Asturias Hospital, University of Alcalá, Anatomical Pathology Department, Alcalá de Henares, Spain,
3
Príncipe de Asturias Hospital, University of Alcalá, Clinical Oncology Department, Alcalá de Henares, Spain
1
P195 Successful treatment of locally advanced Merkel cell carcinoma with somatostatin
analogue‑lanreotide
Lengyel Z.1, Horvath Z.1, Gyulai R.1
University of Pécs, Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary
1
P196 Merkel cell carcinoma with pancreatic metastasis: Case report and review of literature
Costa Filho E.D.P.R.1, Falcão A.C.A.1, Neotti T.2, Costa Junior W.L.3,
Costa F.D.2, Bertolli E.4, Duprat Neto J.P.4
AC Camargo Cancer Center, Surgical Oncology Residence, São Paulo, Brazil, 2AC Camargo Cancer Center, Pathology, São
Paulo, Brazil, 3AC Camargo Cancer Center, Abdominal Surgery Department, São Paulo, Brazil, 4AC Camargo Cancer Center,
Skin Cancer Department, São Paulo, Brazil
1
78
ORPHAN SKIN CANCER
WED
1
EB House Austria, Research Program for Molecular Therapy of Genodermatoses, Department of Dermatology, University
Hospital of the Paracelsus Medical University, Salzburg, Austria, 2Department of Molecular Biology, University of
Salzburg, Salzburg, Austria
Scientific Program
Poster Exhibition
P197 Kaposi sarcoma: General aspect and radiotherapy
Ouaz H.1, Tebra S.1, Zrafi W.1, Bouaouina N.1
University Hospital Farhat Hached, Radiation Oncology, Sousse, Tunisia
P198 Test-retest reproducibility and validity of a skin cancer risk factor questionnaire
Joosten V.H.M.J.1, Wouters L.1, Kelleners‑Smeets N.W.J.1, Nelemans P.J.2
GROW Research Institute for Oncology and Developmental Biology, Dermatology, Maastricht, Netherlands,
CAPHRI School for Public Health and Primary Care, Epidemiology, Maastricht, Netherlands
1
2
P199 Skin cancer incidence in Latvia 2007–2014: comparison with Estonia and Lithuania
Ozola E.1, Donina S.1,2
Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia
P200 Sunbed use: prevalence and estimated risk of melanoma across European countries participating
in the Euromelanoma prevention campaign
Suppa M.1, Gandini S.2, Bulliard J.L.3, Hassane N.1, del Marmol V.1
Université Libre de Bruxelles, Hôpital Erasme, Department of Dermatology, Brussels, Belgium, 2European Institute
of Oncology, Division of Epidemiology, Biostatistics, Milan, Italy, 3Institute of Social and Preventive Medicine (IUMSP),
Lausanne University Hospital, Lausanne, Switzerland
1
P201 Trends in morbidity of Kaposi´s sarcoma among solid organ transplant recipients
Sorin D.1, Hodak E.1,2, Mor E.2,3, Birkenfeld S.4, Davidovici B.1
WED
1
Rabin Medical Center – Beilinson Hospital, Dermatology, Petach Tikva, Israel, 2Sackler Faculty of Medicine,
Tel Aviv University, Tel Aviv, Israel, 3Rabin Medical Center – Beilinson Hospital, Department of Organ Transplantation,
Petach Tikva, Israel, 4Clalit Health Services, Tel Aviv, Israel
THU
P202 Skin cancer: what do you know about it? Moroccan study
Kelati A.1, Meziane M.2, Mernissi F.Z.1
Faculty of Medicine, Hospital Hassan II, Department of Dermatology, Fez, Morocco,
Faculty of Medicine, Hospital Hassan II, Fez, Morocco
1
FRI
2
SAT
P203 Development and application of in vitro keratinocyte assays incorporating viability, p38, p53
endpoints to evaluate the protection efficacy of sunscreens against UV radiation
Stilla A.1, Walter N.1, Hewitt N.J.2, Kunze G.1
Galderma-Spirig Spirig Pharma AG, Egerkingen, Switzerland, 2SWS, Erzhausen, Germany
1
INDEX
P204 Toxiderma drug buprenorphine (Temgesic) in a patient with lung cancer with brain metastases
Boudghene Stambouli O.1
Faculty of Medicine, Dermatology, Tlemcen, Algeria
1
P205 p16 expression in seborrheic keratosis in relation to the presence of Merkel cell polyomavirus
Rennspiess D.1, Hillen L.1, Speel E.‑J.1, Haugg A.2, Winnepenninckx V.1, zur Hausen A.1
POSTER
SKIN CANCER IN GENERAL
1
SCIENTIFIC PROGRAM
1
Maastricht University Medical Center, Pathology, Maastricht, Netherlands, 2Maastricht University Medical Center,
Department of Pathology and GROW-School for Oncology & Developmental Biology, Maastricht, Netherlands
1
79
Scientific Program
Poster Exhibition
Karolinska Institutet, Medicine, Stockholm, Sweden, 2Karolinska Institutet, Oncology-Pathology, Stockholm,
Sweden, 3Karolinska Institutet, Microbiology, Tumor and Cell Biology (MTC), Stockholm, Sweden, 4University of
Turku and Turku University Hospital, Dermatology, Turku, Finland
1
P207 Recurrent nevus vs. recurrent melanoma: Differences in epidemiology and BRAF V600Emutation status
Woltsche N.1, Massone C.1, Klymiuk I.2, Guelly C.2, Zweiker D.3, Bulijan M.1,
Hofmann-Wellenhof R.1, Zalaudek I.1
1
Medical University of Graz, Dermatology & Venereology, Graz, Austria, 2Medical University of Graz, Centre of
Medical Research, Graz, Austria, 3Medical University of Graz, Internal Medicine, Graz, Austria
P208 In vivo multiphoton tomography of skin cancer
Koenig K.1
1
THU
WED
P210
Universität des Saarlandes, Biophotonik und Lasertechnologie, Saarbrücken, Germany
Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival
analysis of KEYNOTE-006
Blank Ch.1, Lorigan P.2, Schachter J.3, Robert C.4 , Ribas A.5, Long G. V.6, Arance A.7, Mortier
L.8, Daud A.9, Carlino M. S.10, McNeil C.11, Lotem M.12, Larkin J.13, Neyns B.14, Petrella T. M.15,
Hamid O.16, Zhou H.17, Ebbinghaus S.17, Ibrahim N.17, Grob J.-J.18
Netherlands Cancer Institute, Amsterdam, Netherlands; 2University of Manchester and the Christie NHS
Foundation Trust, Manchester, United Kingdom; 3Ella Lemelbaum Institute for Melanoma, Sheba Medical
Center, Tel Hashomer, Israel; 4 Gustave Roussy and Paris-Sud University, Villejuif, France; 5University of
California, Los Angeles, Los Angeles, CA;
6
Melanoma Institute Australia, the University of Sydney, Mater Hospital, and Royal North Shore Hospital,
Sydney, Australia; 7Hospital Clinic de Barcelona, Barcelona, Spain; 8Université Lille, Centre Hospitalier Régional
Universitaire de Lille, Lille, France; 9University of California, San Francisco, San Francisco, CA; 10Westmead
and Blacktown Hospitals, Melanoma Institute Australia, and the University of Sydney, Sydney, Australia;
11
Chris O’Brien Lifehouse, Royal Prince Alfred Hospital, and Melanoma Institute Australia, Camperdown,
Australia; 12Sharett Institute of Oncology, Hadassah Hebrew Medical Center, Jerusalem, Israel; 13Royal Marsden
Hospital, London, United Kingdom; 14Universitair Ziekenhuis Brussel, Brussels, Belgium; 15Sunnybrook Health
Sciences Center, Toronto, ON; 16The Angeles Clinic and Research Institute, Los Angeles, CA; 17Merck & Co., Inc.,
Kenilworth, NJ; 18Aix Marseille University, Hôpital de la Timone, Marseille, France
POSTER
INDEX
SAT
FRI
1
80
LATE-BREAKING
SCIENTIFIC PROGRAM
P206 MicroRNA-203 inversely correlates with differentiation grade and suppresses cutaneous
squamous cell carcinoma growth via targeting c-myc oncogene
Lohcharoenkal W.1, Harada M.2, Lovén J.3, Meisgen F.1, Xu Landén N.1, Zhang L.1, Lapins J.1,
Das Mahapatra K.1, Shi H.1, Nissinen L.4, Kähäri V.-M.4, Ståhle M.1, Sonkoly E.1, Grander D.2,
Arsenian-Henriksson M.3, Pivarcsi A.1
Scientific Program
P211
Poster Exhibition
Volume and tissue composition measurements of lymphoedema with DXA scan: A novel
way of measuring lymphoedema
Gjorup C.A.1, Hendel H.W.2, Christensen K.B.3, Dahlstrøm K.1, Drzewiecki K.T.4, Zerahn B.5,
Hölmich L.R.1
Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark,
Herlev Gentofte Hospital, University of Copenhagen, Department of Clinical Physiology and Nuclear Medicine,
PET-Center, Herlev, Denmark, 3Department of Public Health, University of Copenhagen and Department of
Palliative Medicine, Bispebjerg Hospital, Copenhagen, Denmark, 4Department of Plastic Surgery, Breast
Surgery and Burns Treatment, Copenhagen, Denmark, 5Herlev Gentofte Hospital, University of Copenhagen,
Department of Clinical Physiology and Nuclear Medicine, Herlev, Denmark
1
Methyl 5-aminolevulinate photodynamic therapy in the treatment of 112 basal cell
carcinomas in
84 Brazilian patients
Taborda V.1
1
Improving the applicability of guidelines on nonmelanoma skin cancer in frail older
adults: A multidisciplinary expert consensus and systematic review of current guidelines
Lubeek S.F.K.1, Borgonjen R.J.1, Van Vugt L.J.1, Olde Rikkert M.G.2, Van de Kerkhof P.C.M.1,
Gerritsen M.J.P.1
Radboud University Medical Center, Dermatology, Nijmegen, Netherlands, 2Radboud University Medical
Center, Geriatrics, Nijmegen, Netherlands
1
THU
Lymphoedema following sentinel lymph node biopsy and/or complete lymph node
dissection: Impact on health-related quality of life
Gjorup C.1, Grønvold M.2, Dahlstrøm K.1, Drzewiecki K.T.3, Christensen K.B.4, Hendel H.W.5,
Hölmich L.R.1
FRI
P214
Herlev Gentofte Hospital, University of Copenhagen, Department of Plastic Surgery, Herlev, Denmark,
Department of Public Health, University of Copenhagen and Department of Palliative Medicine, Bispebjerg
Hospital, Copenhagen, Denmark, 3Department of Plastic Surgery, Breast Surgery and Burns Treatment,
Copenhagen, Denmark, 4Department of Biostatistics, University of Copenhagen, Copenhagen, Denmark,
5
Department of Clinical Physiology and Nuclear Medicine, PET Center, Herlev Gentofte Hospital, University of
Copenhagen, Herlev, Denmark
1
Comprehensive clinical data review of patients suffering from Mycosis fungoides with
bad outcome
Porkert S.1, Venz M.1, Valencak J.1, Jonak C.1
1
P216
INDEX
P215
SAT
2
POSTER
LATE-BREAKING
P213
Centro de Dermatologia e Laser de Bauru, Photodynamic Therapy Unit, Bauru, Brazil
WED
P212
SCIENTIFIC PROGRAM
2
Medical University of Vienna, Department of Dermatology, Vienna, Austria
Assessment of QOL, illness perception, and illness behavior in 92 patients with primary
cutaneous lymphoma
Porkert S.1, Lehner-Baumgartner E.2, Knobler R.1, Riedl E.1, Jonak C.1
Medical University of Vienna, Department of Dermatology, Vienna, Austria, 2Medical University of Vienna,
Department of Clinical Psychology, Vienna, Austria
1
81
Scientific Program
Dermoscopic and Immunohistochemical changes in acquired Melanocytic Nevi following
phototherapy
Abdel Hay R.1
P218
P219
THU
FRI
SAT
INDEX
POSTER
Lanarkshire Centre for Dermatology, Monklands Hospital, Airdrie, United Kingdom
Peripheral blood lymphocyte subsets in melanoma patients treated with ECHO-7 virus
and control
Ozola E.1, Sālījuma E.1, Doniņa S.1,2
1
82
Faculty of Medicine, Cairo University, Dermatology, Cairo, Egypt
Clinical outcome of high-risk primary cutaneous squamous cell carcinoma three years
after initial treatment at a Scottish dermatology centre
Ngu S.T.1, Gupta P.1, Gupta R.1, Gupta G.1
1
WED
SCIENTIFIC PROGRAM
1
Rigas Stradins University, Riga, Latvia, 2Riga East University Hospital, Riga, Latvia
LATE-BREAKING
P217
Poster Exhibition
EADO
I N D UST RI A L E XH I B ITI O N
List of Exhibitors 85
Exhibition Floor Plan 84
FSA Disclosure Requirement 87
t
ost recen
Get the m
rch
a
e
s
re
on on
ti
a
rm
fo
in
by
ent care
and pati
o ur
h
it
ing w
exchang
rs.
e
n
rt
pa
industr y
Industrial Exhibition
Exhibition Floor Plan
INDUSTRIAL EXHIBITION
The industrial exhibition takes place in the Hofburg Galerie, in the Seitengalerie and in
the Oberes Platzl.
Marmorsaal
Geheime Ratstube
r
Antekamme
Rittersaal
Hofburg Lounge
Hofburg Galerie
Lift
Zeremoniensaal
Oberes Platzl
Seitengalerie
Heldenplatz
Speakers Preview Room
Festsaal
Heldenplatz
Opening Hours
WED, August 31
THU, September 1
FRI, September 2
SAT, September 3
84
01:30 PM–07:00 PM
09:00 AM–05:30 PM
09:00 AM–05:30 PM
09:00 AM–12:30 PM
Exhibitor
3Gen, Inc./DermLite
List of Exhibitors
Booth No.
7
Amgen
21
Biofrontera Pharma GmbH
11
Bristol-Myers Squibb
22
Canfield Scientific, Inc.
14
Derma Medical Systems Handels- und Entwicklungs GmbH
1
Dermo Scan GmbH
3
Elekta
FotoFinder Systems GmbH
Heine Optotechnik GmbH & Co. KG
IGEA SpA Clinical Biophysics
10
4
23
5
Incyte Corporation
13
Integra
19
MAVIG GmbH VivaScope Systems Confocallasermicroscopy
16
MEDlight
6
Merck-Pfizer Alliance
8
Merck-Pfizer Alliance
17
Mirai Medical
MSD
Nevisense by SciBase
2
18
9
Novartis
20
Provectus Biopharmaceuticals, Inc.
15
Therakos
12
Vielgesundheit
24
Wisepress Medical Bookshop
25
85
INDUSTRIAL EXHIBITION
Industrial Exhibition
Epacadostat is an investigational,
novel oral immunotherapy that inhibits
indoleamine-2,3-dioxygenase 1 (IDO1)
OPEN FOR ENROLLMENT
NCT02752074
ENROLLING
COMBINATION
INVESTIGATION
A phase 3 study
of epacadostat and
pembrolizumab
Patients with
unresectable or
metastatic melanoma
Incyte and Merck
combination
investigational study:
ECHO-301/KEYNOTE-252
RANDOMIZATION
PHASE 3
Epacadostat +
Pembrolizumab
CO-PRIMARY ENDPOINTS
Progression-Free Survival
Overall Survival
Pembrolizumab
This study will enroll in the following regions: North America,
Central/South America, Europe, Australia, and Other Select Countries
Contact us to learn if any of your patients may be eligible for participation in ECHO-301
1-855-4MEDINFO (1-855-463-3463) / [email protected]
The efficacy and safety of the investigational compounds discussed have not been
established. There is no guarantee that these compounds will become commercially
available for the use(s) under investigation.
© 2016, Incyte Corporation. All rights reserved. INC-1172 06/16
Industrial Exhibition
FSA Disclosure Requirement
B:216 mm
S:180 mm
T:210 mm
BIOPHARMACEUTICALS, INC.
Advancing a New Front
in the
War Against Cancer
Amgen
€95,000 (Platinum Sponsor)
Biofrontera Pharma GmbH
€2,850 (Exhibition Space)
Bristol-Myers Squibb
€102,850 (Platinum Sponsor)
Elekta
€4,275 (Exhibition Space)
FotoFinder Systems GmbH
€2,850 (Exhibition Space)
Integra
€3,800 (Exhibition Space)
Merck-Pfizer Alliance
€67,125 (Gold Sponsor)
MSD
€95,000 (Platinum Sponsor)
Provectus Biopharmaceuticals,
Inc.
€19,000 (Bronze Sponsor
& Lanyards)
Therakos
€2,850 (Exhibition Space)
INDUSTRIAL EXHIBITION
According to the guidelines of the FSA Code of Conduct or other codes, we disclose the
financial support of:
87
Imprint
Scientific Organization
Hubert Pehamberger & Christoph Hoeller
Medical University Vienna
Department of Dermatology
Währinger Gürtel 18–20
1090 Vienna, Austria
Legal Organizer & PCO
MCI Deutschland GmbH
MCI | Berlin Office
Markgrafenstrasse 56
10117 Berlin, Germany
P:+49 (0)30 204590
F: +49 (0)30 2045950
E: [email protected]
VAT ID number: DE 114406202, Local Court Berlin-Charlottenburg, HRB 100620B
Managing Directors: Gunda Stickan, Gerrit Jessen, Andreas Laube
Print
Lehmann Offsetdruck GmbH
Picture Credits
Cover page: © TTstudio – Fotolia.com (1), © kameraauge – Fotolia.com (2)
Editorial Deadline
August 8, 2016
All information is supplied without liability and is subject to change.
88
STRONGER
TOGETHER
Combine COTELLIC with Zelboraf to achieve powerful efficacy
in patients with BRAF V600(+) metastatic melanoma1
Cotellic® 20 mg film-coated tablets
Qualitative and quantitative composition: Each film-coated tablet contains cobimetinib hemifumarate equivalent to 20 mg
cobimetinib. Excipient with known effect: Each film-coated tablet contains 36 mg lactose monohydrate. List of excipients: Tablet
core: Lactose monohydrate, Microcrystalline cellulose (E460), Croscarmellose sodium (E468), Magnesium stearate (E470b).
Film coating: Polyvinyl alcohol, Titanium dioxide (E171), Macrogol 3350, Talc (E553b). Therapeutic indications: Cotellic is
indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma
with a BRAF V600 mutation (see sections 4.4 “Special warnings and precautions for use” and 5.1 “Pharmacodynamic properties”
of the officially published Summary of Product Characteristics). Contraindications: Hypersensitivity to the active substance or
to any of the excipients. Marketing Authorisation Holder: Roche Registration Limited, 6 Falcon Way, Shire Park, Welwyn Garden
City, AL7 1TW, United Kingdom General classification of supply: Product on prescription, supply through pharmacies only.
Pharmacotherapeutic group: Antineoplastic agents, ATC code: L01XE38
For special warnings and precautions for use, interactions with other medicinal products and other forms of interaction as
well as information on pregnancy and lactation and on undesirable effects please refer to the officially published
Summary of Product Characteristics. December 2015.
1. Larkin J, et al. N Eng J Med 2014; 371:1867-1876.
For further information, please visit www.roche-cotellic.com
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.
Healthcare professionals are asked to report any suspected adverse reactions. Adverse events should be reported to Bundesamt
für Sicherheit im Gesundheitswesen, Traisengasse 5, 1200 Wien, Fax: + 43 (0) 50 555 36207, Website: http://www.basg.gv.at/ and
to Roche Austria GmbH, www.roche.at.
PR/COBI/1603/0003
April 2016
For patients with regionally or distantly
metastatic melanoma, stage IIIB, IIIC and IVM1a*
IMLYGIC®
(talimogene laherparepvec)
NOW
APPROVED
IN THE EU
INJECT THE LESION.
IGNITE AN IMMUNE RESPONSE.
THAT’S THE PRECISION OF IMLYGIC®.
*Indication
IMLYGIC® is indicated for the treatment of adults with unresectable melanoma that is regionally or
distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease (see
sections 4.4 and 5.1 of the Summary of Product Characteristics).1
Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer
Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer
Nebenwirkung zu melden. Hinweise zur Meldung von Nebenwirkungen, siehe Abschnitt 4.8 der Fachinformation.
Fachkurzinformation
Imlygic 106 Plaque-bildende Einheiten (PFU)/ml Injektionslösung
Imlygic 108 Plaque-bildende Einheiten (PFU)/ml Injektionslösung
Qualitative und Quantitative Zusammensetzung:
Jede Durchstechflasche enthält 1 ml entnehmbares Volumen Imlygic
in einer nominalen Konzentration von 1 x 106 (1 Million) respektive
1 x 108 (100 Millionen) Plaque-bildenden Einheiten (PFU)/ml.
Sonstige Bestandteile mit bekannter Wirkung: Jede Dosis von 4 ml
enthält ungefähr 30 mg (1,3 mmol) Natrium und 80 mg Sorbitol.
Liste der sonstigen Bestandteile:
Dinatriumphosphat-Dihydrat, NatriumdihydrogenphosphatDihydrat, Natriumchlorid, Myo-Inositol, Sorbitol (E420), Wasser für
Injektionszwecke.
Anwendungsgebiete:
Imlygic ist indiziert zur Behandlung von Erwachsenen mit nicht
resezierbarem, lokal oder entfernt metastasiertem Melanom
(Stadium IIIB, IIIC und IVM1a) ohne Knochen-, Hirn-, Lungen- oder
andere viszerale Beteiligung.
Gegenanzeigen:
Patienten mit einer Vorgeschichte einer Überempfindlichkeit gegen
Talimogen laherparepvec oder einen der sonstigen Bestandteile.
• Patienten, die schwer immungeschwächt sind (z. B. Patienten mit schwerer
angeborener oder erworbener zellulärer und/oder humoraler Immunschwäche).
Pharmakotherapeutische Gruppe: Antineoplastische und
immunmodulierende Mittel, ATC-Code: L01XX51.
Inhaber der Zulassung: Amgen Europe B.V., 4817 ZK Breda, NL,
Vertreter in Österreich: Amgen GmbH, 1040 Wien.
Verschreibungspflicht / Apothekenpflicht: Rezept- und
apothekenpflichtig.
Stand der Information: Juli 2016
Weitere Angaben zu Dosierung und Dauer der Anwendung, besonderen
Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung,
Wechselwirkungen mit anderen Arzneimitteln und sonstigen
Wechselwirkungen, Fertilität, Schwangerschaft und Stillzeit sowie zu
Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation.
For further information please consult the Summary of Product Characteristics (SmPC).
Reference: 1. Imlygic Summary of Product Characteristics.
© 2016 Amgen Inc. All rights reserved. EUHQ-P-678x-0116-122547. August 2016